TEXAS STATE VITA

Liqin Du, MD, PHD

Assistant Professor of Biochemistry
Department of Chemistry and Biochemistry
College of Science and Engineering
Texas State University

Academic/Professional Background

A. Educational Background

PHD, University of Kentucky, USA.

MS, Shanghai Second Medical University (Shanghai Jiao Tong University School of Medicine), China.

BM (MD equivalent), Shanghai Medical University (Shanghai Medical College of Fudan University), China.

B. University Experience

Position	*University*	*Dates*
Associate Professor with Tenure	Texas State University (Texas State)	2021 - Present
Assistant Professor	Texas State	2015 - 2021
Adjunct Assistant Professor	UT Health Science Center at San Antonio	2015 - 2021
Research Assistant Professor	UT Health Science Center at San Antonio	2013 - 2015
Instructor	UT Health Science Center at San Antonio	2012 - 2013
Assistant Instructor	UT Southwestern Medical Center at Dallas	2009 - 2011
Post-doctoral fellow	UT Southwestern Medical Center at Dallas	2005 - 2009
Lecturer	Shanghai Second Medical University, China	1998 - 1999
Research Assistant	Institute of Neurology, Fudan University, China	1992 - 1995

Honors and Awards (Total 4; ****, Since 2021, 2)**

**4) Recipient, 2025 CoSE Excellence in Scholarly/Creative Activities Award, Texas State University..

**3) Recipient, 2024 Presidential Research Award for Faculty Development Leave (2024 Fall semester), Texas State University.

2) Nominee, 2020 Dreyfus Teacher-Scholar Award, Texas State University.

1) Nominee, 2020 Presidential Award for Excellence in Scholarly/Creative Activities, Texas State University.

I. TEACHING, pages 2 - 12

II. RESERCH, pages 12 - 27

III. SERVICE, pages 27 – 29

1. TEACHING

B. Lectures (Texas State):

CHEM 4375/5375 - Biochemistry

CHEM 4481 – Advanced Biochemistry Lab I

CHEM 5383 – Molecular Biology and Genetics

CHEM 5386 – Proteins (as co-instructor)

CHEM 5387 – Nucleic Acids

CHEM 7110 – Advances in Molecular and Biophysical Chemistry

C. Undergraduate/Graduate Research (Texas State):

BIO 5314 – Research Experience

BIO 5399 – Thesis

BIO 7114/7214/7314 – Research Experience

BIO 7303 – Research

CHEM 4382 – Advanced Biochemistry Lab II

CHEM 4299 – Undergraduate research

CHEM 4371 – Directed Study

CHEM 5199/5299/5399 – Thesis Research

MSEC 7303 – Research MSEC

MSEC 7199/7399/7699/7999 - Dissertation

RES 4399 – Undergraduate Research (IDEA scholar)

D. Directed Student Learning (theses, dissertations, undergraduate research, etc.):

(, since 2021, 67)**

**114) Applied Research Project, "Discovering novel anti-cancer drug candidates for neuroblastoma" Status: In progress. (September 22, 2025 - Present).
Advised: Mary Faneye

**113) Applied Research Project, " Discovering novel anti-cancer drug candidates for neuroblastoma " Status: In progress. (September 15, 2025 - Present).
Advised: Marc Frons

**112) Applied Research Project, "Investigating the anti-cancer activities on small-molecule compounds." Status: In progress. (October 3, 2025 - Present).
Advised: Camila Mendoza

**111) Applied Research Project, "Investigating the anti-cancer activities of differentiation-inducing microRNAs." Status: In progress. (September 24, 2025 - Present).
Advised: Eva Solorzano, , IDEA program

**110) Applied Research Project, "Investigating the correlation of differentiation-blocking gene expression with neuroblastoma patient survival." Status: In progress. (September 15, 2025 - Present).
Advised: Jillian Jenkins

**109) Applied Research Project, "Investigating the clinical relevance of differentiation-blocking genes." Status: In progress. (September 15, 2025 - Present).
Advised: Megan Hall

**108) Applied Research Project, "Anti-cancer activities of differentiation-inducing microRNAs." Status: In progress. (September 3, 2025 - Present).
Advised: Rose Bhavika, IDEA program

**107) Applied Research Project, "Differentiation inducing activities of microRNAs." Status: In progress. (August 1, 2025 - Present).
Advised: Sydney Kirchem

**106) Applied Research Project, "Anti-cancer activity of novel compounds in neuroblastoma." Status: In progress. (June 26, 2025 - Present).
Advised: Nathan Hua

**105) Applied Research Project, "Anti-cancer activity of novel compounds." Status: In progress. (January 2025 - Present).
Advised: Melissa Salinas

**104) Dissertation, "Identifying novel druggable receptors that control neuroblastoma cell differentiation." Status: In progress. (June 1, 2025 - present).
Advised: Saika Anne, Biology PhD

**103) Master's Thesis, "Optimization of molecular buoys for nucleic acid capture in liquid biopsy." Status: In progress. (September 10, 2025 - present).
Advised: Niharika Bhattarai

**102) Master's Thesis, "Defective repair of double-strand breaks and oxidative DNA damage drives aberrant cell cycling in S. cerevisiae." Status: In progress. (September 5, 2025 - present).
Advised: Bryce Jones

**101) Master's Thesis, "Investigating the differential response of neuroblastoma cell line to differentiation-inducing microRNAs." Status: In progress. (September 3, 2025 - present).
Advised: Nayana Syama Prasad, Biochem MS

**100) Applied Research Project, "Anti-cancer activity of colchicine and CA4." Status: Completed. (May 25, 2025 - August 20, 2025).
Advised: Luis Antopia

**99) Supervisor / Chair, Applied Research Project, "Anti-cancer activity of novel compounds." Status: In progress. (January 2025 - Present).
Advised: Jordyn Pollard

**98) Supervisor / Chair, Applied Research Project, "Novel genes that control neuroblastoma cell differentiation." Status: In progress. (December 2024 - Present).
Advised: Bennet Harris

**97) Supervisor / Chair, Applied Research Project, "Anti-cancer activity of novel compounds." Status: Completed. (September 2024 – May 2025).
Advised: Elijah Garza

**96) Supervisor / Chair, Applied Research Project, "Anti-cancer activity of novel compounds." Status: Completed. (September 2024 – May 2026).
Advised: Kevin Tat, IDEA program

**95) Supervisor / Chair, Applied Research Project, "Anti-cancer activity of novel compounds." Status: Completed. (June 2024 – December 2025).
Advised: Diego Hernandez-Barcenas, IDEA program

**94) Supervisor / Chair, Applied Research Project, "Mechanisms that control neuroblastoma cell survival and differentiation." Status: Completed. (January 15, 2024 – May 2025).
Advised: Joseph Beau Sciba

**93) Supervisor / Chair, Applied Research Project, "Anti-cancer activity of novel compounds in neuroblastoma." Status: Completed. (January 2024 – May 2025).
Advised: Ana Cadena

**92) Supervisor / Chair, Applied Research Project, "Differentiation-inducing activity of miR-506-3p analogs." Status: in progress. (January 2024 - Present).
Advised: Brynn Del Buono

**91) Supervisor / Chair, Applied Research Project, "Anti-cancer activity of novel heterocyclic compounds." Status: in progress. (January 2024 – May 2026).
Advised: Jaedyn Ramirez, U-RISE

**90) Supervisor / Chair, Applied Research Project, "Anti-cancer activity of novel heterocyclic compounds." Status: in progress. (January 2024 – May 2026).
Advised: Kieran Ross, U-RISE, REU

**89) Dissertation, "Exploring novel therapeutic strategies for drug-resistant childhood Ewing Sarcoma." Status: in progress. (August 2020 – May 2025).
Advised: Samson Ghilu, MSEC PhD

**88) Dissertation, "Identifying novel druggable genes that control neuroblastoma cell differentiation." Status: in progress. (January 2025 - May 9, 2028).
Advised: Tanzila Kamal Choity. MSEC PhD

**87) Master's Thesis, "Investigating the response of neuroblastoma cell line to differentiation agents." Status: in progress. (December 2024 - May 9, 2026).
Advised: Salina Malek. Biology MS

**86) Master's Thesis, "Immunogenic modulation of cancer using PEDOT nanoparticle mediated photothermal therapy." Status: Completed. (October 22, 2023 - May 9, 2025).
Advised: Sarah Mithcell

**85) Master's Thesis, "Investigating roles of nonhomologous end-joining and recombination genes in repair of site-specific DNA double-stranded breaks in Saccharomyces cerevisiae" Status: Completed. (August 30, 2023 - May 9, 2025).
Advised: Anika Mahmood

**84) Master's Thesis, "Identifying subpopulation of neuroblastoma cells that are resistant to differentiation -inducing agents - Anupa Parajuli." Status: Completed. (August 2023 - May 9, 2025).
Advised: Anupa Parajuli, Biochem MS

**83) Supervisor / Chair, Applied Research Project, "Novel compounds that reduce neuroblastoma cell viability - Kaitlyn Costilla." (October 2023 - December 2024).
Advised: Kaitlyn Costilla, IDEA program

**82) Supervisor / Chair, Master's Thesis, "Investigating the Differential Responses of Neuroblastoma Cell Lines to MiR-506-3p and Retinoic Acid Treatment - Alex Vernaza." Status: Completed. (January 2023 - December 9, 2024).
Advised: Alexandra Vernaza, SURE, STDBP, Biochem MS

**81) Supervisor / Chair, Applied Research Project, "Establishing ATRA-resistant neuroblastoma cell lines - Emma Lewis." (June 15, 2023 - August 2024).
Advised: Emma Lewis

**80) Supervisor / Chair, Applied Research Project, "Anti-cancer activity of novel compounds in neuroblastoma - Allie Wesner." Status: Completed. (January 2024 - May 2024).
Advised: Allie Wesner

**79) Supervisor / Chair, Applied Research Project, "Novel compounds that reduce neuroblastoma cell viability - Elizabeth Hampton." Status: Completed. (October 2023 - May 2024).
Advised: Elizabeth Hampton, undergraduate

**78) Master's Thesis, "DESCRIBING THE CELL BIOLOGY of Saprolegnia parasitica: ROLE of METALS AND RESPIRATION - Rahima Akter." Status: Completed. (April 1, 2023 - May 9, 2024).
Advised: Rahima Akter, MS

**77) Master's Thesis, "BASE EXCISION REPAIR AND HOMOLOGOUS RECOMBINATION ARE REQUIRED FOR THE MAINTENANCE OF CELLULAR HOMEOSTASIS IN SACCHAROMYCES CEREVISIAE - Sanjida Ahmed." (March 1, 2023 - May 9, 2024).
Advised: Sanjida Ahmed, MS

**76) Master's Thesis, "The Phosphorylation of LaRP6 Modulates its Interactions with Serine-Threonine Kinase Receptor Associated Protein - Ezra Hackler." Status: Completed. (October 30, 2022 - May 9, 2024).
Advised: Ezra Hackler, MS

**75) Master's Thesis, "Identifying Target Genes of MiR-506-3p that Mediate its Differentiation-Inducing Activity and Developing Differentiation-Inducing MiR-506-3p Analogs - Daniela Cardus." Status: Completed. (June 2022 - May 9, 2024).
Advised: Daniela Cardus, STDBP, Biochem MS

**74) Supervisor / Chair, Applied Research Project, "Novel compounds that reduce neuroblastoma cell viability - Matthew Michaels." Status: Completed. (February 2023 - December 2023).
Advised: Matthew Michaels, undergraduate

**73) Supervisor / Chair, Applied Research Project, "Correlation of CDKN3 expression with neuroblastoma patient survival - Angela Zhang." Status: Completed. (March 2023 - September 2023).
Advised: Angela Zhang, high school student

**72) Supervisor / Chair, Applied Research Project, “Determining the differentiation-inducing activities of retinoic acid and miR-506-3p in neuroblastoma cell lines” Status: Completed. (October 2023 – December 2024).
Advised: Taylor Beckford, IDEA student, Undergraduate, Bachelor of Science.

**71) Supervisor / Chair, Applied Research Project, "Survival and differentiation analysis of neuroblastoma cells," Status: In Progress. (November 2022 - Present). Biochemistry, Texas State University.
Advised: Ella Shifman, Undergraduate, Bachelor of Science

**70) Supervisor / Chair, Applied Research Project, "Identifying novel molecules that induce cell differentiation or reduce cell survival in neuroblastoma cells," Status: Completed. (September 2022 – May 2025). Biochemistry, Texas State University.
Advised: Jadyn Smith, Undergraduate, Bachelor of Science, MaNair Scholar

**69) Supervisor / Chair, Applied Research Project, "Bioinformatics analysis of miR-506-3p target genes," Status: In Progress. (September 1, 2022 – May 2024). Biochemistry, Texas State University.
Advised: Mackenize Toliver, Undergraduate

**68) Supervisor / Chair, Applied Research Project, "Survival analysis of neuroblastoma cells," Status: Completed. (September 2022 – May 2024). Biochemistry, Texas State University.
Advised: Monica Malhotra, Undergraduate

**67) Supervisor / Chair, Applied Research Project, "High-throughput screening of cytotoxic heterocyclic compounds in neuroblastoma cells," Status: Completed. (June 1, 2022 – May 2023). Biochemistry, Texas State University.
Advised: Hannah Simpson, Undergraduate, U-RISE

**66) Supervisor / Chair, Applied Research Project, "Identifying novel heterocycles that reduce neuroblastoma cell viability," Status: Completed. (June 1, 2022 - Present). Biochemistry, Texas State University.
Advised: Kathryn Rhodes, Undergraduate, U-RISE

**65) Supervisor / Chair, Applied Research Project, "Identifying novel compounds that reduce neuroblastoma cell survival," Status: Completed. (August 1, 2022 - December 2022). Biochemistry, Texas State University.
Advised: Vincent Do, Undergraduate, Bachelor of Science, IDEA program

**64) Supervisor / Chair, Applied Research Project, "Identifying novel differentiation-inducing compounds for treating neuroblastoma," Status: Completed. (January 4, 2022 - May 10, 2022). Chemistry, Texas State University.
Advised: Corbyn Voboril, Undergraduate

**63) Supervisor / Chair, Applied Research Project, "Identifying novel anti-cancer compounds for cancer treatment", Status: Completed. (October 1, 2021 – May, 2022). Chemistry, Texas State University.
Advised: Tuan Ngo, Undergraduate

**62) Supervisor / Chair, Applied Research Project, "Identifying novel differentiation-inducing compounds for treating neuroblastoma", Status: Completed. (September 2021 - May, 2022). Chemistry, Texas State University.
Advised: Christian Martinez, Undergraduate

**61) Supervisor / Chair, Applied Research Project, "Identifying novel anti-cancer compounds for cancer treatment", Status: Completed. (September 2021 - May, 2022). Chemistry, Texas State University.
Advised: Marcus Blanco, Undergraduate

**60) Member, Master's Thesis, "Macrophage Reprograming for Cancer Immunotherapy using Albumin nanoparticle-mediated Photothermal therapy and Chemotherapy", Status: Completed. (May 27, 2021 – December 2021). Chemistry and Biochemistry, Texas State University.
Advised: Wasan Al-Sammarraie, Graduate

**59) Supervisor / Chair, Applied Research Project, "Identifying novel anti-cancer compounds for treating neuroblastoma", Status: Completed. (February 2, 2021 – August, 2022). Chemistry, Texas State University.
Advised: Juan Pimentel, Undergraduate

**58) Supervisor / Chair, Applied Research Project, "Developing miR-506-3p mimics with differentiation activity", Status: Completed. (January 20, 2021 – May, 2022). Biochemistry, Texas State University.
Advised: Morgan Connor, Undergraduate

**57) Member, Master's Thesis, "DNA repair mechanisms: homologous recombination pathway", Status: Completed. (December 18, 2020 – July, 2022). Chemistry and Biochemistry, Texas State University.
Advised: Armand Berry, Graduate, MS.

**56) Supervisor / Chair, Master's Thesis, "Developing miR-506-3p analogs with improved differentiation-inducing activity", Status: Completed. (August 2020 – July, 2022). Chemistry and Biochemistry, Texas State University.
Advised: Nakya Mesa-Diaz, Graduate, Master of Science.

**55) Supervisor / Chair, Applied Research Project, "Investigating the oncogenic impact of gene CDKN3 in neuroblastoma patients", Status: Completed. (April 2020 – December 2022). Biology, Texas

State University.
Advised: Alexandra Vernaza, Undergraduate, SURE program

**54) Member, Master's Thesis, "Cell Cycle Dependent Involvement of MRX in Double-Strand Break Repair via Non-Homologous End Joining", Status: Completed. (August 2020 - December 2021). Chemistry and Biochemistry, Texas State University.
Student(s): Diego Valdez-Oranday, Graduate, Master of Science.

**53) Supervisor / Chair, Applied Research Project, "Determining the differentiation-inducing activity of a novel miR-506-3p analog in neuroblastoma cells", Status: Completed. (March 5, 2021 - August 5, 2021). Biology, Texas State University.
Advised: Mary Maya, Undergraduate, SURE program

**52) Supervisor / Chair, Applied Research Project, "Developing miR-506-3p analogs with enhanced differentiation-inducing activity", Status: Completed. (January 22, 2021 - July 2021). Biology, Texas State University.
Advised: Emma Huff, Undergraduate

**51) Member, Master's Thesis, "Defects in base excision repair (BER) are linked to changes in cell cycling in Saccharomyces cerevisiae", Status: Completed. (December 4, 2020 - July 2021). Chemistry and Biochemistry, Texas State University.
Advised: Yogesh Nepal, Graduate, Master of Science.

**50) Member, Master's Thesis, "Nanomedicine-Mediated Reprogramming of Tumor Immunogenicity", Status: Completed. (May 2020 - July 2021). Chemistry and Biochemistry, Texas State University.
Advised: Emilio Lara, Graduate, Master of Science.

**49) Supervisor / Chair, Applied Research Project, "Understanding the interactions of miR-506-3p with its targets", Status: Completed. (January 15, 2021 - May 2021). Biochemistry, Texas State University.
Advised: Mitchell Smith, Undergraduate

48) Supervisor / Chair, Applied Research Project, "Characterizing the anti-cancer mechanisms of Rooperol", Status: Completed. (November 1, 2019 – May 2020). Biochemistry, Texas State University.
Advised: Christian Cifuentes, Undergraduate

47) Supervisor / Chair, Applied Research Project, "Optimization of plasmid transformation protocol in E. coli cells", Status: Completed. (October 30, 2019 – May, 2020). Biochemistry, Texas State University.
Advised: Benjamin Collier, Undergraduate, Bachelor of Science.

46) Supervisor / Chair, Applied Research Project, "Correlation of p42.3 gene expression with adult and pediatric cancer patient survival", Status: Completed. (October 1, 2019 – May, 2020). Biochemistry, Texas State University.
Advised: Reagan Webber, Undergraduate

45) Supervisor / Chair, Applied Research Project, "Overexpression of miR-124 and miR- 506 in neuroblastoma cells using expression vectors", Status: Completed. (October 1, 2019 – May, 2020). Biochemistry, Texas State University.
Advised: Robert Tomestic, Undergraduate

44) Supervisor / Chair, Applied Research Project, "Identifying miR-506-3p target genes that regulate neuroblastoma cell differentiation", Status: Completed. (October 1, 2019 – May 2020). Biochemistry, Texas State University.
Advised: Tehya McClendon, Undergraduate

43) Member, Candidacy Exam, "Advances in aptamer discovery and application", Status:

Completed. (September 9, 2019 - November 22, 2019). Biochemistry, Texas State University.
Advised: Rebecca Marks, Graduate, Master of Art.

42) Supervisor / Chair, Master's Thesis, "Cell Cycle Regulator SAPCD2 as a Novel Oncogene in Pediatric Neuroblastoma", Status: Completed. (August 26, 2019 – July 2021). Chemistry and Biochemistry, Texas State University.
Advised: Amy Baker, Graduate, Biochem MS.

41) Supervisor / Chair, Applied Research Project, "Novel anti-cancer drugs for neuroblastoma and melanoma", Status: Completed. (June 2019 – May 2020). Biochemistry, Texas State University.
Advised: Liana Tamez, Undergraduate

40) Supervisor / Chair, Applied Research Project, "miR-506-3p regulate expression of transcription factors PLAGL2 and MYCN in neuroblastoma", Status: Completed. (April 2, 2019 - June 4, 2019). Biochemistry, Texas State University.
Advised: Collin Bryant, Undergraduate

39) Supervisor / Chair, Applied Research Project, "Discovering target genes of miR-506-3p that mediates its tumor suppressive function", Status: Completed. (January 22, 2019 – May 6, 2019). Biochemistry, Texas State University.
Advised: Kaitlin Walla, Undergraduate

38) Member, Master's Thesis, "Novel neuroblastoma differentiation agents", Status: Completed. (October 2018 – May 2020). Chemistry and Biochemistry, Texas State University.
Advised: Breana Laguera, Graduate

37) Member, Master's Thesis, "Synthesis of Caffeic acid phenethyl amide and analogues for cytotoxicity analysis to improve metabolic stability", Status: Completed. (October 2018 – May 2020). Chemistry and Biochemistry, Texas State University.
Advised: Mauricio Jemal, Graduate

36) Supervisor / Chair, Applied Research Project, "Improve DNA gel electrophoresis protocol", Status: Completed. (October 2018 – May 2019). Biochemistry, Texas State University.
Advised: Seth Paniagua, Undergraduate

35) Supervisor / Chair, Project, "Identification of Anti-cancer drugs for neuroblastoma", Status: Completed. (October 2018 – August 2019). Biology, Texas State University.
Student(s): Andrew Gonzales, Undergraduate

34) Supervisor / Chair, Master's Thesis, "Characterizing the anti-cancer activity of three novel differentiation-inducing compounds", Status: Completed. (September 2018 – May 2020). Chemistry and Biochemistry, Texas State University.
Advised: Alex Oviedo, Graduate, STDBP, Biochem MS

33) Supervisor / Chair, Master's Thesis, "Determining the cellular response of neuroblastoma cells to miR-506-3p expression", Status: Completed (September 2018 – December 2022). Chemistry and Biochemistry, Texas State University.
Advised: Nathaniel Belnap, Graduate

32) Supervisor / Chair, Applied Research Project, "Identifying synthetic compounds that induce neuroblastoma cel death and differentiation", Status: Completed. (September 2018 – May 2019). Biochemistry, Texas State University.
Advised: Courtney Steed, Undergraduate

31) Supervisor / Chair, Applied Research Project, "Identifying natural products that induce neuroblastoma cell death", Status: Completed. (August 2018 – May 2019). Biochemistry, Texas State University.

Advised: Carlos Duenas, Undergraduate

30) Supervisor / Chair, Applied Research Project, "Anti-cancer activity of light sensitive compounds", Status: Completed. (July 2018 – May 2019). Biochemistry, Texas State University.
Advised: Amy Baker, Undergraduate

29) Supervisor / Chair, Applied Research Project, "correlation of candidate oncogenes and tumor suppressor genes with cancer patient survival", Status: Completed. (July 2018 – May 2019). Biochemistry, Texas State University.
Advised: Soroush Omidvarnia, Undergraduate

28) Supervisor / Chair, Project, "Mechanisms by which miR-506-3p regulates MYCN expression in neuroblastoma cells", Status: Completed. (October 2017 – May 2018). Biology, Texas State University.
Advised: Ashley Engbrock, Undergraduate

27) Member, Master's Thesis, "Role of spontaneous DNA damage and single-stranded DNA in generation of enlarged G2 phase cells in rad52 mutants of Saccharomyces cerevisiae", Status: Completed. (January 2017 - December 2018). Chemistry and Biochemistry, Texas State University.
Advised: Corbin England, Graduate

26) Supervisor / Chair, Project, "Novel compounds that induce neuroblastoma cell differentiation and reduce cell survival", Status: Completed. (August 2017 - August 2018). Biology, Texas State University.
Advised: Evelynn Shanks, Undergraduate

25) Supervisor / Chair, Applied Research Project, "Making protein ladder used for Western blot analysis", Status: Completed. (October 2017 - May 2018). Biochemistry, Texas State University.
Advised: Luke Fuller, Undergraduate

24) Supervisor / Chair, Undergraduate Research, “Culturing neuroblastoma cell lines”, Status: In Progress. (October 2017 - May 2018). Biology, Texas State University.
Advised: Holase Howard, Undergraduate

23) Supervisor / Chair, Undergraduate Research, “Culturing neuroblastoma cell lines”, Status: In Progress. (October 2017 - May 2018). Biology, Texas State University.
Advised: Vivianna Cavazos, Undergraduate

22) Supervisor / Chair, Applied Research Project, "Identifying cytotoxic rooperol analogs for neuroblastoma cells", Status: In Progress. (September 2017 - May 2018). Biochemistry, Texas State University.
Advised: Mary Rodebaugh, Undergraduate

21) Member, Master's Thesis, “Stability studies of rooperol and analogues by in vitro metabolism with HPLC/MS detection”, Status: Completed. (September 2017 - May 2019). Chemistry and Biochemistry, Texas State University.
Advised: Amanda Bohanon, Graduate

20) Member, Master's Thesis, “Glucuronide prodrug of a naturally derived cytotoxic product”, Status: Completed. (September 2017 - May 2019). Chemistry and Biochemistry, Texas State University.
Advised: Brandie Tylor, Graduate

19) Supervisor / Chair, Master's Thesis, "Determining the Function of Vacuolar (H+)- ATPase in Regulating Neuroblastoma Cell Survival and Differentiation", Status: Completed. (January 23, 2017 - May 2018). Chemistry and Biochemistry, Texas State University.
Advised: Geraldo Medrano, Graduate, STDBP, Biochem MS

18) Member, Master's Thesis, "Mechanisms of Cell Death Caused by Photothermal Ablation of Cancer Cells Mediated by Conductive Polymer Nanoparticles.", Status: Completed. (November 1, 2016 - May 2018). Chemistry and Biochemistry, Texas State University.
Advised: Madeline Huff, Graduate

17) Supervisor / Chair, Applied Research Project, "miR-506-3p regulates MYCN expression in neuroblastoma through down regulation of RXRα, specifically truncated RXRα", Status: Completed. (January 19, 2016 - May 5, 2018). Biology/Biochemistry, Texas State University.
Advised: Spencer Shelton, Undergraduate

16) Supervisor / Chair, Applied Research Project, "Overexpression of VATP06E in neuroblastoma cells", Status: Completed. (October 2017 - March 2018). Biochemistry, Texas State University.
Advised: Raul Nava, Undergraduate

15) Supervisor / Chair, Undergraduate Research, “Novel anti-cancer mechanisms in neuroblastoma”, Status: Completed. (January 24, 2017 - December 2017). Biology, Texas State University.
Advised: Cox Grant, Undergraduate

14) Supervisor / Chair, Master's Thesis, "Investigation of the therapeutic potential of miR- 506-3p in neuroblastoma", Status: Completed. (October 1, 2015 - August 2017). Chemistry and Biochemistry, Texas State University.
Advised: Michaela Sousares, Graduate

13) Supervisor / Chair, Master's Thesis, "Investigation of the role of CDKN3 in neuroblastoma cell differentiation", Status: Completed. (October 1, 2015 - August 2017). Chemistry and Biochemistry, Texas State University.
Advised: Veronica Partridge, Graduate

12) Supervisor / Chair, Applied Research Project, "Novel compounds that reduce neuroblastoma survival", Status: Completed. (January 18, 2017 - July 2017). Biology, Texas State University.
Advised: Derek Rodriguez, Undergraduate

11) Member, Master's Thesis, "Aptamer targeted drug delivery and cell-surface biomarker identification for hepatocellular carcinoma", Status: Completed. (July 1, 2016 - July 2017). Chemistry and Biochemistry, Texas State University.
Advised: Elizabeth McIvor, Graduate

10) Supervisor / Chair, Undergraduate Research, “Novel anti-cancer mechanisms in neuroblastoma”, Status: Completed. (January 20, 2017 - May 2017). Biology, Texas State University.
Advised: Michael Jones, Undergraduate

9) Supervisor / Chair, Applied Research Project, "Novel compounds that reduce neuroblastoma survival", Status: Completed. (August 29, 2016 - May 2017). Chemistry and Biochemistry, Texas State University.
Advised: Jordan Johnson, Undergraduate

8) Member, Master's Thesis, "Sphaeropsidin A for Cancer Treatment", Status: Completed. (January 1, 2016 - May 2017). Chemistry and Biochemistry, Texas State University.
Advised: Robert Scott, Graduate

7) Supervisor / Chair, Undergraduate research, “Novel anti-cancer mechanisms in neuroblastoma”, Status: Completed. (September 8, 2015 - May 2017). Biology, Texas State University.
Advised: Christian Teague, Undergraduate

6) Member, Master's Thesis, "DNA double-strand break repair deficiency is associated with changes in

cell cycling and cell morphology in Saccharomyces cerevisiae", Status: In Progress. (September 1, 2015 - May 2017). Chemistry and Biochemistry, Texas State University.
Advised: Monica Weis, Graduate, Biology MS.

5) Member, Master's Thesis, "Quantitate assessment of changes in cellular morphology and cell division number during telomere-initiated senescence in the yeast Saccharomyces cerevisiae", Status: Completed. (January 1, 2016 - December 2016). Chemistry and Biochemistry, Texas State University.
Advised: Shubha Malla, Graduate, MS.

4) Supervisor / Chair, Applied Research Project, "Oncogenic role of p42.3 in lung cancer", Status: Completed. (March 6, 2016 - November 1, 2016). Biology, Texas State University.
Advised: Daniel Hernandez, Undergraduate

3) Member, Master's Thesis, "Role of genes affecting telomere lengths, chromatin remodeling, and cell cycle checkpoints in maintenance of chromosome stability in Yeast YKU70 mutant", Status: Completed. (January 1, 2016 - July 2016). Chemistry and Biochemistry, Texas State University.
Advised: Angelica Riojas, Graduate, MS.

2) Supervisor / Chair, Undergraduate Research, “Optimizing neuroblastoma cell culturing techniques”, Status: Completed. (January 29, 2016 - May 9, 2016). Chemistry and Biochemistry, Texas State University.
Advised: Victoria Sanchez, Undergraduate

1) Supervisor / Chair, Undergraduate Research, “Optimizing neuroblastoma cell culturing techniques”, Status: Completed. (January 20, 2016 - May 9, 2016). Chemistry and Biochemistry, Texas State University.
Advised: Cullen Nisson, Undergraduate

E. Student Accomplishments:

1. *Awards:* (Total, 6; **, since 2021, 3)

**6) Mentor, 2024 Texas TRI Matthew W.Taylor Scholarship Award. "1) Discovering Novel Druggable Targets for Neuroblastoma Differentiation Therapy from the Human Kinome; 2) Investigating Activity of miR-506-3p Against Cell Viability and Cell Morphology in Lung and Cervical Cancers." Status: Completed. (August 2024). Texas State University.
Student(s): Jadyn Smith.

**5) Mentor, 2023 Scott Emerson Health Innovation Award. "Identification of Potential Anti-Cancerous Activity in Neuroblastoma from a Heterocyclic Compound Library," Spring 2023 Undergraduate Research Conference, San Marcos, TX. Status: Completed. (April 20, 2023).
Student(s): Jadyn Smith, Undergraduate, BS.

**4) Mentor, Best Presentation Award. "Identifying heterocyclic compounds with anti-cancer potential in neuroblastoma," 2022 UT-Austin Fall Undergraduate Research Symposium (UT-FURS), Austin, TX. Status: Completed. (September 24, 2022).
Student(s): Hannah Simpson, Undergraduate.

3) Mentor, Top Master's Poster Award. "Cell Cycle Regulator SAPCD2 Contributes to Poor Prognosis in Pediatric Neuroblastoma," 11th Annual International Research Conference for Graduate Students, Texas State University. Status: Completed. (November 5, 2019). Chemistry and Biochemistry, Texas State University.
Student(s): Amy Baker, Graduate, Master of Science.

2) Mentor, Outstanding undergraduate research award. "RXRA is a direct target gene of miR-506-3p that regulates MYCN expression and cell differentiation in neuroblastoma," Texas State University.

Status: Completed. (March 2018). Chemistry and Biochemistry, Texas State University.
Student(s): Spencer Shelton, Undergraduate, BS.

1) Mentor, First Place Undergraduate Poster Presentation Award. "RXRA is a direct target gene of miR-506-3p that regulates MYCN expression and cell differentiation in neuroblastoma," 2017 Department of Biochemistry and Structural Biology Annual Retreat in UT Health Science Center at San Antonio (UTHSCSA), UT Health Science Center at San Antonio (UTHSCSA). Status: Completed. (November 3, 2017). Chemistry and Biochemistry, Texas State University.
Student(s): Spencer Shelton, Undergraduate.

2. ***Peer-reviewed Journal Articles:*** **(**since 2021, 10) (**see page 13, **1. Published Journal Articles)**

3. ***Poster and Oral Presentations:*** **(**since 2021, 45) (**see page 17, **3. Poster Presentations)**

I. RESEARCH

A. Funding

1. Funded External Grants: (total, 9; **<u>*, since 2021, 3</u>)**

10) **Du, L. (PI). Discovering targets for neuroblastoma differentiation therapy from human druggable genome, National Institute of Health, NCI, Federal, $531,550.00. (R15CA305329-01, 7/4/2025 – 6/30/ 2028).

9) Peterson, R. L. (PI), Lewis, L. (Co-I), **Du, L. (Co-I), McLean, R. J. C. (Co-I), "Fluorescence Microscope with Live-cell and high-resolution imaging capabilities," Sponsored by NIH, Federal, $194,590.30. (1S10GM154304-01, July 1, 2024 - June 30, 2025).

8) **Du, L. (PI). Molecular and therapeutic mechanisms of differentiation-inducing microRNA miR-506-3p in neuroblastoma, National Institute of Health, NCI, Federal, $445,639.00. (1R15CA249653-01, 9/1/2020 – 8/31/ 2024).

7) **Du, L.** (**PI**), Kornienko, Alexander (co-I), Houghton, Peter (collaborator). Discovery of new differentiation agents for neuroblastoma therapy, National Institute of Health, NCI, Federal, $461,574.00. (1R15CA213199-01A1, 8/1 2017 – 7/31/2020).

6) Kerwin, S (PI), **Du, L. (Co-PI)**. Hypoxis-derived treatment for advanced lung cancer, William and Ella Owens Medical Research Foundation, Private / Foundation / Corporate, $153,109.00. (Funded: January 1, 2016 - December 31, 2017).

5) **Du, L. (PI)**. Identifying microRNAs that induce neuroblastoma cell differentiation, Department of Defense, Federal, $186,828.00. (PR151532, 9/1/2013 – 2/28/2017). Transferred to Texas State.

4) **Du, L. (PI)**. Identifying a novel oncogenic mechanism and diagnostic marker for neuroendocrine lung cancer, Peter Bradley Carlson Trust, $30,000.00. (1/1/2015 – 12/31/2015).

3) Cichewicz, R. (PI), Mooberry, S. (co-PI), **Du, L. (co-I)**, Identify bioactive natural products from the Great Lakes fungi for treating pediatric cancers, National Institute of Health, NIGMS, Federal, $861,335.00. (1R01GM107490-01A1, 7/1/ 2014 – 6/30/ 2018).

2) Pertsemlidis, A. (PI), **Du, L. (Co-PI)**. What drives the regression in neuroblastoma? Clues from Chromosome 21, Helen Freeborn Kerr Foundation Award, Private / Foundation / Corporate, $4,000.00. (7/1/2014 – 6/30/2015).

1) **Du, L (PI)**. Discovery of new drugs for neuroblastoma from Texas plants, Bank of America Shelby Rae Tengg Foundation, Private / Foundation / Corporate, $5,000.00. (7/1/ 2013 – 6/30/2014).

2. Funded Internal Grants: (total, 8; ****, since 2021, 3)**

8) **Du, L (PI). Targeting the human druggable genome for neuroblastoma differentiation therapy, REP Program, Texas State University, Texas State University, $8,000.00. (1/27/2025 – 5/31/2026).

7) **Du, L (PI). To develop new research directions in my laboratory during developmental leave. Presidential Research Award, Texas State University, $20,000.00. (7/2/2024 – 5/31/2025).

6) **Du, L (PI). Developing novel miR-506-3p analogs that induce neuroblastoma cell differentiation, REP Program, Texas State University, Texas State University, $8,000.00. (1/15/2020 – 12/31/2021).

5) **Du, L (PI)**. Determining the therapeutic potential of rooperol in neuroblastoma, REP Program, Texas State University, Texas State University, $8,000.00. (1/1/2017 – 5/31/2018).

4) Pertsemlidis, A (PI), **Du, L (Co-PI)**. Elucidating how chromosome 21 protects against neuroblastoma occurrence, Institute for Integration of Medicine and Science, Institutional (Higher Ed), $50,000.00. (10/4/2014 – 9/30/2015).

3) **Du, L (PI)**. Identifying microRNAs that regulate LMO1 expression in neuroblastoma, Greehey Children's Cancer Research Institute, Institutional (Higher Ed), $8,100.00. (8/1/2013 – 7/31/2015).

2) **Du, L (PI)**. Identifying long non-coding RNAs controlling neuroblastoma cell differentiation, Institute for Integration of Medicine and Science, Institutional (Higher Ed), $50,000.00. (12/1/2013 – 11/30/2014).

1) **Du, L (PI)**. Pilot investigation of the role of microRNAs in regulating neuroblastoma cell differentiation. Greehey Children's Cancer Research Institute, Other, $10,000.00. (9/1/2012 – 8/31/2013).

B. Peer-reviewed Journal Articles:)

1. Published Journal Articles: (total, 52; #, undergraduate in my lab; $, graduate in my lab *, corresponding author, 17; **, **since 2021, 16)**

52) Aksenov, D. ., Fernandez, G. E., Kuzminov, I. K., Arutiunov, N. A., Aleksandrova, E. V., Aksenov, A. V., Vernaza, A., #Ramirez, J., #Ross, K., #Smith, J. L., **Du, L., Sathish, P., Tantillo, D. J., Kornienko, A. Convenient synthesis and antiproliferative activity of 2-(Indol-2-yl)-2-arylacetamides. *Tetrahedron.* 2025; 175: 134515. *Impact factor: **2.457***.

51) Saucedo, A., Subbarao, M., Jemal, M., $Mesa-Diaz, N. L., #Smith, J. L., $Vernaza, A., **Du, L., and Kerwin. S. M. Flow and On-Water Synthesis and Cancer Cell Cytotoxicity of Caffeic Acid Phenethyl Amide (CAPA) Derivatives. *Int. J. Mol. Sci.* **2024**; 25: 8051. *Impact factor: **5.6***.

50) $Cardus, D.F., #Smith, M.T., $Vernaza, A., #Smith, J. L., #Del Buono, B., $Parajuli, A., #Lewis, E.G., Mesa-Diaz, N., ***Du, L. (2024) Systematic Analysis of miR-506-3p Target Genes Identified Key Mediators of Its Differentiation-Inducing Function. *Genes.* 2024;15(10): 1268. *Impact factor: **2.8.***

49) Aksenov, D. A., #Smith J. L., Aksenov, A. V., Prityko, L. A., Aksenov, N. A., Kuzminov, I. K., Aleksandrova, E. V., Sathish, P., $Mesa-Diaz, N., $Vernaza, A., Zhang, A., **Du, L., Kornienko, A. 2-(3-Indolyl)acetamides and their oxazoline analogues: Anticancer SAR study. (2024) *Bioorg. Med. Chem. Lett.* 102, 129681. *Impact factor: **2.94.*** DOI: 10.1016/j.bmcl.2024.129681

48) $Vernaza, A., $Cardus, D. F., #Smith, J. L., $Partridge, V., $Baker, A. L., #Lewis, E. G., Zhang, A., Zhao, Z., ***Du, L. Identification of CDKN3 as a Key Gene that Regulates Neuroblastoma Cell Differentiation. (2024) *Journal of Cancer*, *15*(5), 1153–1168. *Impact factor: **3.9*** DOI: 10.7150/jca.89660

47) $Mesa-Diaz, N., #Smith, M.T., $Cardus, D.F., ***Du, L. (2023) Development of Shortened miR-506-3p Mimics Exhibiting Strong Differentiation-Inducing Activity in Neuroblastoma Cells. *Molecules,*

28(17), 6295. *Impact factor:* ***4.927*** doi: 10.3390/molecules28176295.

46) [#]Johns, A.C., [$]Oviedo. A., Zhao. Z., ***Du. L., *Kornienko, A. Discovery of 5-sulfonyltetrazoles as neuroblastoma differentiation agents. (2023). *Bioorg Med Chem Lett*, 94, 129455. *Impact factor:* ***2.823*** doi: 10.1016/j.bmcl.2023.129455.

45) Stollmaier, J. G., Thomson, J., Endoma-Arias, M A., Simionescu, R., [#]Vernaza, A., [$]Mesa-Diaz, N., [#]Smith, M.T., **Du, L., Kornienko, A., Hudlicky, T. (2022). Conversion of Natural Narciclasine to Its C-1 and C-6 Derivatives and Their Antitumor Activity Evaluation: Some Unusual Chemistry of Narciclasine. *Molecules, 27,* 4141. *Impact factor:* ***4.927***. https://doi.org/10.3390/molecules27134141.

44) Habaz, L., Korey Bedard, K., [#]Smith, M.T, **Du, L., Kornienko, A., Hudlicky, T. (2022). Design and Synthesis of C-1 Methoxycarbonyl Derivative of Narciclasine and Its Biological Activity. *Molecules, 27,* 3809. *Impact factor:* ***4.927***. https://doi.org/10.3390/molecules27123809

43) Schwartz, Z. T., Theisen, P. D., Bjornstal, O. T., [#]Rodebaugh, M., Jemal, M. A., Lee, D., Shelton, S. D., Zhao, Z., **Du, L., Sean M. Kerwin, S. M. (2022). Scalable Synthesis and Cancer Cell Cytotoxicity of Rooperol and Analogues. *Molecules, 27,* 1792. *Impact factor:* ***4.927***. https://doi.org/10.3390/molecules27061792

42) [$]Baker, A. L., ***Du, L. (2022). The function and regulation of SAPCD2 in physiological and oncogenic processes. *J Cancer*, 13(7), 2374-2387. Review. *Impact factor:* ***4.207***.

41) Aksenov, A. V., Arutiunov, N. A., Kirilov, N. K., Aksenov, D. A., Grishin, I. Y., Aksenov, N. A., Wang, H., **Du, L., Betancourt, T., Pelly, S., Kornienko, A., Rubin, M. (2021). [3+2]-Annulation of pyridinium ylides with 1-chloro-2-nitrostyrenes unveils a tubulin polymerization inhibitor. *Organic & Biomolecular Chemistry*, *19*, 7234. *Impact factor:* ***3.876***.

40) Ticli, V., Zhao, Z., **Du, L., Kornienko, A. V., & Hudlicky, T. (2021). Synthesis and biological evaluation of 10-benzyloxy-Narciclasine. *Tetrahedron*, *101*, 132505. *Impact factor:* ***2.457***.

39) Zhao, G., **Du, L., Zhang, L., & Jia, Y. (2021). LIM domain only 1: an oncogenic transcription cofactor contributing to the tumorigenesis of multiple cancer types. *Chinese Medicine Journal*, *134*(9), 1017–1030. https://doi.org/10.1097/CM9.0000000000001487

38) Rastogi, S. K., Dunnigan, J. K., Towne, A. C., Zhao, Z., **Du, L., & Brittain, W. J. (2021). Photopharmacology of Azo-Combretastatin-A4: Utilizing Tubulin Polymerization Inhibitors and Green Chemistry as the Key Steps. *Current Organic Chemistry*, *25*, 2457. *Impact factor:* ***1.933***. https://doi.org/10.2174/1385272825666210526151222

37) Rastogi, S. K., Zhao, Z., Gildner, M. B. C., Shoulders, B. A., Velasquez, T. L., Blumenthal, M. O., **Du, L., Brittain, W. J. (2021). Synthesis, optical properties and in vitro cell viability of novel spiropyrans and their photostationary states. *Tetrahedron*, *80*, 131854. *Impact factor:* ***2.457***.

36) Aksenov, N. A., Aksenov, A. V., Kirilov, N. K., Arutiunov, N. A., Aksenov, D. A., Maslivetc, V., Zhao, Z., **Du, L**., Rubin, M. Kornienko, A. V. (2020). Nitroalkanes as electrophiles: synthesis of triazole-fused heterocycles with neuroblastoma differentiation activity. *Organic & Biomolecular Chemistry*, *18*(34), 6651–6664. *Impact factor:* ***3.876***. https://doi.org/https://doi.org/10.1039/D0OB01007C

35) Eyong, K. O., Ketsemen, H. L., Zhao, Z., **Du, L.,** Ingels, A., Mathieu, V., Hull, K. G., Folefoc, G. N., Baskaran, S., Romo, D. (2020). Anti-proliferative activity of naphthoquinones and indane carboxylic acids from lapachol against a panel of human cancer cell lines. *Medicinal Chemistry Research*, *29*, 1058–1066. *Impact factor:* ***2.351***.

34) Zhao, Z., [#]Shelton, S. D., [$]Oviedo, A., [$]Baker, A. L., [#]Bryant, C. P., [#]Omidvarnia, O., ***Du, L.**, (2020). The PLAGL2/MYCN/miR-506-3p interplay regulates neuroblastoma cell fate and associates with neuroblastoma progression. *J Exp and Clin Cancer Res, 39(1), 41.*

Impact factor: ***5.646.*** doi: 10.1186/s13046-020-1531-2

33) Kosti, A., **Du, L.**, Shivram, H., Qiao, M., Burns, S., Garcia, J. G., Pertsemlidis, A., Iyer, V. R., Kokovay, E., Penalva, L. O. F., (2019). *ELF4* Is a Target of miR-124 and Promotes Neuroblastoma Proliferation and Undifferentiated State. *Mole Cancer Res*, *18*(1), 68–78. *Impact factor:* ***4.484.*** https://doi.org/10.1158/1541-7786.MCR-19-0187

32) Aksenov, A. V., Aksenov, D. A., Arutiunov, N. A., Aksenov, N. A., Aleksandrova, E. V., Zhao, Z., **Du, L.**, Kornienko. A., Rubin, M. (2019). Synthesis of Spiro[indole-3,5'-isoxazoles] with Anticancer Activity via a Formal [4 + 1]-Spirocyclization of Nitroalkenes to Indoles. *The J Org Chem*, *84*(11), 7123–7137. https://doi.org/10.1021/acs.joc.9b00808. *Impact factor:* ***4.805***

31) Zhao, Z., [$]Partridge, V., [$]Sousares, M., [#]Shelton, S. D., Holland, C., Pertsemlidis, A., &

Du, L**. (2018). microRNA-2110 functions as a tumor suppressor in neuroblastoma by directly targeting *Tsukushi*. *PLOS One*, *13*(12), e0208777. *Impact factor:* ***2.776

30) ***Du, L.**, Zhao, Z., Suraokar, M., [#]Shelton. S. D., Ma, X., Hsiao, T. H., MInna, J. D., Wistuba, I., Pertsemlidis. A., LMO1 functions an oncogene through regulating TTK expression and correlates with neuroendocrine differentiation of lung cancer. *Oncotarget*. 2018; *9*, 29601– 29618. *Impact factor:* ***5.008*** (2016).

29) Yu, X., Zhang, Y., Cavazos, D., Ma, X., Zhao, Z., **Du, L.**, & Pertsemlidis, A. (2018). miR- 195 targets cyclin D3 and survivin to modulate the tumorigenesis of non-small cell lung cancer. *Cell Death Dis*, *9*(2), 193. *Impact factor:* ***5.959***

28) Rastogi, S. K., Zhao, Z., Barrett, S. L., [#]Shelton, S. D., Zafferani, M., Anderson, H. E., Blumenthal. M. O., Jones. L.R., Wang. L., Li. X., Streu. C.N., **Du. L.**, Brittain, W. J. (2018). Photoresponsive azo-combretastatin A-4 analogues. *Eur J Med Chem*, *143*, 1–7. https://doi.org/10.1016/j.ejmech.2017.11.012. *Impact factor:* ***4.816***

27) [$]Sousares, M., [$]Partridge, V., Weigum, S., & ***Du, L**. (2017). MicroRNAs in neuroblastoma differentiation and differentiation therapy. *Adv Mod Oncol Res*, *3*(5), 213. https://doi.org/10.18282/amor.v3.i5.233

26) Li, L.-Y., Ma, R.-L., ***Du, L.**, & Wu, A.-S. (Published). Ozonated autohemotherapy modulates the serum levels of inflammatory cytokines in gouty Patients. *J Open Acc Rheu: Res Rev*. *Impact factor:* ***0.85***

25) [$]Partridge, V., [$]Sousares, M., Zhao, Z., & ***Du, L**. (2017). Current understanding on the role of cell cycle regulators in neuroblastoma. *Med One*, *2*, e170010. https://doi.org/10.20900/mo.20170010

24) Zhao, Z., Ma, X., [#]Shelton, S. D., Sung, D. C., Li, M., [#]Hernandez, D., Zhang, M., Losiewicz, M. D., Chen, Y., Pertsemlidis, A., Yu, X., Liu, Y., ***Du, L**. (2016). A combined gene expression and functional study reveals the crosstalk between N-Myc and differentiation-inducing microRNAs in neuroblastoma cells. *Oncotarget*, *7*(48), 79372–79387. https://doi.org/10.18632/oncotarget.12676. *Impact factor:* ***5.008*** (2016)

23) Zhao, Z., Ma, X., Sung, D., Li, M., Kosti, A., Lin, G., … ***Du, L.** (2015). microRNA-449a functions as a tumor suppressor in neuroblastoma through inducing cell differentiation and cell cycle arrest. *RNA Biol*, *12*(5), 538–554. *Impact factor:* ***5.216***

22) Borkowski, R., **Du, L.**, Zhao, Z., McMillan, E., Kosti, A., Yang, C., Suraokar, M., Wistuba, I.I., Gazdar, A. F., Minna, J. D., White, M. A., Pertsemlidis, A. (2015). Genetic Mutation of p53 and Suppression of the 3 miR-17-92 Cluster Are Synthetic Lethal in Non–Small Cell Lung Cancer due to Upregulation of Vitamin D Signaling. *Cancer Res*, *75*(4), 666–75. https://doi.org/10.1158/0008-5472. *Impact factor:* ***9.130***

21) Zhao, Z., Ma, X., Hsiao, T., Lin, G., Kosti, A., Yu, X., Suresh, U., Chem, Y., Tomlinson, G. E., Pertsemlidis, A., ***Du, L.** (2014). A high-content morphological screen identifies novel microRNAs that regulate neuroblastoma cell differentiation. *Oncotarget*, *5*(9), 2499–512. *Impact factor:* ***5.008***

(2016)

20) ***Du, L.**, Zhao, Z., Ma, X., Hsiao, T., Chen, Y., Young, E., Suresh, U., Chem, Y., Tomlinson, G. E., Pertsemlidis, A. (2014). miR-93-directed down-regulation of DAB2 defines a novel oncogenic pathway in lung cancer. *Oncogene*, *33*, 4307–4315. *Impact factor: **6.854***

19) **Du, L.**, Borkowski, R., Zhao, Z., Yu, X., Ma, X., & Pertsemlidis, A. (2013). A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel. *RNA Biol*, *10*(11), 1700–1713. *Impact factor: **5.216***

18) **Du, L.**, & Pertsemlidis, A. (2012). microRNA regulation of cell viability and drug sensitivity in lung cancer. *Exp Opin Biol Ther*, *12*(9), 1221–1239. *Impact factor: **3.974***

17) **Du, L.**, Subauste, M., DeSevo, C., Zhao, Z., Baker, M., Borkowski, R., Schageman J.J., Greer, G., Yang, C., Suraokar, M., Wistuba, I.I., Gazdar, A. F., Minna, J. D., Pertsemlidis, A. (2012). miR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non- small cell lung cancers. *PLOS One*, *7*(6), e39167. *Impact factor: **2.776***

16) **Du, L.**, & Pertsemlidis, A. (2011). Cancer and neurodegenerative disorders: pathogenic convergence through microRNA regulation. *J Mol Cell Biol*, *3*(3), 176–80. *Impact factor: **4.671***

15) Subauste, M., Ventura-Holman, Lu, D., **Du, L**., Sansoma, O., & Maher, J. (2011). Fem1b antigen in the stool of Apc (Min) mice as a biomarker of early Wnt signaling activation in intestinal neoplasia. *Cancer Epidemiol*, *35*(1), 97–100. *Impact factor: **2.619***

14) Nikolic, D., Calderon, L., **Du, L.**, & Post, S. (2011). SR-A ligand and M-CSF dynamically regulate SR-A expression and function in primary macrophages via p38 MAPK activation. *BMC Immunol*, *12*, 37–46. *Impact factor: **2.615***

13) Subauste, M., Sansom, O., Porecha, N., Raich, N., **Du, L.**, & Maher, J. (2010). Fem1b, a proapoptotic protein, mediates proteasome inhibitor-induced apoptosis of human colon cancer cells. *Mol Carcinog*, *49*(2), 105–13. *Impact factor: **3.411***

12) ***Du, L.**, Schageman, J., Irnov, Girard, L., Hammond, S., Minna, J., Gazdar, A. F., Pertsemlidis, A. (2010). microRNA expression distinguishes SCLC from NSCLC lung tumor cells and suggests a possible pathological relationship between SCLCs and NSCLCs. *J Exp Clin Cancer Res*, *29*, 75. *Impact factor: **5.646***

11) **Du, L.**, & Pertsemlidis, A. (2010). microRNAs and lung cancer: tumors and 22-mers.

Cancer Metast Rev, *29*(1), 109–22. *Impact factor: **6.667***

10) Gibbons, D., Lin, W., Creighton, C., Rizvi, Z., Gregory, P., Goodall, G., Thilaganathan. N., **Du. L.**, Zhang. Y., Pertsemlidis. A., Kurie, J. (2009). Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. *Genes Dev*, *23*(18), 2140–2151. *Impact factor: **8.990***

9) ***Du, L**., Schageman, J., Subauste, M., Saber, B., Hammond, S., Prudkin, L., Wistuba, I. I., Ji, L., Roth, J. A., Minna, J. D., Pertsemlidis, Pertsemlidis, A. (2009). miR-93, miR-98 and miR-197 regulate expression of tumor suppressor gene. *FUS1. Mol Cancer Res*, *7*(8), 1234–1243. *Impact factor: **4.484***

8) Subauste, M., Ventura-Holman, T., **Du, L.**, Subauste, J., Chan, S., Yu, V., & Maher, J. (2009). RACK1 downregulates levels of the pro-apoptotic protein Fem1b in apoptosis-resistant colon cancer cells. *Cancer Biol Ther*, *8*(23), 2297–2305. *Impact factor: **2.879***

7) **Du, L.**, & Post, S. (2004). Macrophage-colony stimulating factor differentially regulates low-density lipoprotein and transferrin receptor. *J Lipid Res*, *45*(9), 1733–1740. *Impact factor: **4.743***

6) **Du, L.**, Cheng, W., Shi, Q., & Jin, H. (2000). Effect of selenium on the immune responses in normal-immune and immune suppressed mice. *J Shanghai 2nd Med Univ*, *20*(1), 29–31.

5) **Du, L.**, Cheng, W., Shi, Q., & Gao, M. (2000). Toxic effects of selenium on normal- immune and immune-suppressed mice. Shanghai Trace Elements. *Shanghai Trace Elements*, *1*(3), 18–21.

4) **Du, L.**, & Cheng, W. (1999). Selenium and Immune Responses. *Foreign Med Sci (Pub ealth)*, *26*(2), 91–94.

3) **Du, L.**, & Cheng, W. (1998). Clinical use of selenium in parenteral nutrition. *Foreign Med Sci (Medical Geology)*, *19*(1), 4–8.

2) Tian, M., Ye, K., **Du, L.**, & Li, Y. (1994). Assay of hemoagglutinin inhabitation antibody to hemorrhaghic fever virus. *Shanghai J Med Lab Sci*, *9*(1), 40–41.

1) Ye, K., **Du, L.**, Tian, M., Zhou, L., Li, Y., & Yu, Z. (1993). An investigation on wild animal reservoir infected with epidemic hemorraghic fever. *Chinese J Pub Health*, *12*(6), 352–354.

2. Patents: (Since 2021, 1 - pending)

Du, L. "Novel truncated miRNA-506-3p analogs for Neuroblastoma differentiation therapy." (Submitted: January 10, 2023, Application: January 10, 2023). *Pending.*

Du, L. "microRNA composition in the treatment of neuroblastoma". International. Number / ID: US10087444 B2. (Date received: 2018).

3. Poster Presentations: (total, 88; **<u>**, since 2021, 45</u>)**

(#, Texas State Undergraduate; $, Texas State graduate)

**88) Ross, K. (First Author/Presenter), Ramirez, J. (co-author), Vernaza, A. (co-author), Aggarwal, A. M. (co-author), Odeh, M. A. (co-author), Rastogi, S. K. (Sponsor/mentor/author), Du, L. (Sponsor/mentor/author), 2025 Summer RICE showcase - REU, "Determining the Cytotoxicity of Photoisomeric Spiropyran Compounds on Cancer Cells - Kieran, poster," Texas State University, San Marcos, TX, United States. (July 17, 2025).

**87) Hernandez-Barcenas, D. (First Author/Presenter), Du, L. (Sponsor/mentor/author), 2025 summer RICE showcase - IDEA center, "Assessing Colchicine Sensitivity in BE(2)-C Neuroblastoma Cells: Cytotoxicity Analysis - Diego, poster," Texas State University, San Marcos, TX, United States. (July 17, 2025).

**86) Del Buono, B. (First Author/Presenter), Du, L. (Sponsor/mentor/author), 2025 Spring TXST Undergraduate Research Conference, "Determining the differentiation-inducing activities of synthetic miR-506-3p mimics in neuroblastoma cells - Brynn, poster," Texas State University, San Marcos, TX, United States. (April 23, 2025).

**85) Hernandez-Barcenas, D. (First Author/Presenter), Du, L. (Sponsor/mentor/author), 2025 Spring TXST Undergraduate Research Conference, "Investigating the cytotoxic effect of Colchicine on neuroblastoma - Diego, poster," Texas State University, San Marcos, TX, United States. (April 23, 2025).

**84) Ross, K. (First Author/Presenter), Ramirez, J. (co-author), Vernaza, A. (co-author), Aggarwal, A. M. (co-author), Odeh, M. A. (co-author), Rastogi, S. K. (Sponsor/mentor/author), Du, L. (Sponsor/mentor/author), 2025 Spring TXST STEM conference, "Determining the Effectiveness of Three Spiropyran Compounds to Hinder the Malignant Growth of Cancer Cells- Kieran, poster," Texas State University, San Marcos, TX, United States. (March 28, 2025).

**83) Ramirez, J. (First Author/Presenter), Smith, J. (co-author), Ross, K. (co-author), Kornienko, A. V. (Author), Du, L. (Sponsor/mentor/author), 2025 Spring TXST STEM conference, "Identifying novel Heterocyclic Compounds that have anti-cancer potential in Neuroblastoma - Jaedyn," Texas State University, Pittsburgh, PA, United States. (March 28, 2025).

**82) Smith, J. L. (First Author/Presenter), Du, L. (Sponsor/mentor/author), 2025 Spring TXST STEM conference, "Utilizing the Human Kinome to Identify Potential Oncogenic Blockers of Neuroblastoma Differentiation - Jadyn, poster," Texas State University, San Marcos, TX, United States. (March 28, 2025).

**81) Costilla, K. (First Author/Presenter), Du, L. (Sponsor/mentor/author), Fall 2024 TXST Undergraduate Research Conference - Talk, "Comparing Activity of Two Heterocyclic Compounds in Targeting Malignant Neuroblastoma Cells - Kaitlyn, Talk," Texas State University, San Marcos, TX, United States. (November 22, 2024).

**80) Smith, J. L. (First Author/Presenter), Du, L. (Sponsor/mentor/author), Fall 2024 TXST Undergraduate Research Conference, "Discovering Novel Druggable Targets for Neuroblastoma Differentiation Therapy from the Human Kinome - Jadyn, Talk," Texas State University, San Marcos, TX, United States. (November 22, 2024).

**79) Ross, K. (First Author/Presenter), Ramirez, J. (co-author), Vernaza, A. (co-author), Aggarwal, A. M. (co-author), Odeh, M. A. (co-author), Rastogi, S. K. (Sponsor/mentor/author), Du, L. (Sponsor/mentor/author), 2024 The Annual Biomedical Research Conference for Minority Students (ABRCMS), "Examining the Effectiveness of Two Spiropyran Compounds to Hinder the Malignant Growth of Cancer Cells - Kieran," ABRCMS, Pittsburgh, PA, United States. (November 15, 2024).

**78) Ramirez, J. (First Author/Presenter), Smith, J. (co-author), Ross, K. (co-author), Kornienko, A. V. (Author), Du, L. (Sponsor/mentor/author), 2024 The Annual Biomedical Research Conference for Minority Students (ABRCMS), "Identifying novel Heterocyclic Compounds that have anti-cancer potential in neuroblastoma - Jaedyn," ABRCMS, Pittsburgh, PA, United States. (November 15, 2024).

**77) Costilla, K. (First Author/Presenter), Du, L. (Sponsor/mentor/author), Fall 2024 Undergraduate Research Conference - IDEA origram, "Comparing IC50 of Two Heterocyclic Compounds in Targeting Malignant Neuroblastoma Cell Line -BE(2)-C - Kaitlyn," Texas State University, San Marcos, TX, United States. (November 15, 2024).

**76) Smith, J. L. (First Author/Presenter), Du, L. (Sponsor/mentor/author), 2024 McNair Fall Research Seminar, "Investigating Activity of miR-506-3p Against Cell Viability and Cell Morphology in Lung and Cervical Cancers - Jadyn, Talk," Texas State University, San Marcos, TX, United States. (November 15, 2024).

**75) Parajuli, A. (First Author/Presenter), Du, L. (Sponsor/mentor/author), 2024 TXST 3-Minute Thesis Competition, "Identifying neuroblastoma cells resistant to differentiation-inducing agents - Anupa, Talk," Texas State University, San Marcos, TX, United States. (November 8, 2024).

**74) Ross, K. (First Author/Presenter), Rastogi, S. K. (Mentor/author), Du, L. (Sponsor/mentor/author), 2024 University of Texas at Austin Fall Undergraduate Research Symposium (UT-FURS), "Determining the Anti-Cancer Potency of Two Spiropyran Compounds on Cancer Cells - Kieran, Talk," Austin, TX, United States. (October 5, 2024).

**73) Ramirez, J. (First Author/Presenter), Du, L. (Sponsor/mentor/author), 2024 University of Texas at Austin Fall Undergraduate Research Symposium (UT-FURS), "Identifying novel Heterocyclic Compounds that have anti-cancer potential in Neuroblastoma - Jaedyn, Talk," Austin, TX, United States. (October 5, 2024).

**72) Ross, K. (First Author/Presenter), Rastogi, S. K. (Mentor/author), Du, L. (Sponsor/mentor/author), 2024 Texas State College of Science & Engineering Summer Research Symposium, "Examining the Effectiveness of Two Heterocyclic Compounds to Hinder the Malignant Growth of HeLa cells - Kieran," San Marcos, TX, United States. (July 26, 2024).

**71) Ramirez, J. (First Author/Presenter), Smith, J. (co-author), Kornienko, A. V. (Mentor/author), Du, L. (Sponsor/mentor/author), 2024 Texas State College of Science & Engineering Summer Research Symposium, "Identification of Heterocyclic compounds as Potential Anticancer Agents - Jaedyn," San Marcos, TX, United States. (July 26, 2024).

**70) Ghilu, S. (First Author/Presenter), Robles, A. J. J. (Author), Zheng, S. (Author), T., R. K., Du, L. (Mentor), Houghton, P. J. (Sponsor/mentor/author), 2024 NCI T32 and Cancer Biology Training Programs, "Elucidating drug resistance mechanisms in childhood cancer using a new approach that incorporated clinical heterogeneity - Sam," Greehey Children's Cancer Research Institute - UT Health San Antonio, San Antonio, TX. (April 22, 2024).

**69) Beckford, T. (First Author/Presenter), Du, L. (Sponsor/mentor/author), 2024 TXST STEM Conference, "Investigating the Differentiation-Inducing Activity of All-Trans Retinoic Acid on Neuroblastoma Cells - Talyor," San Marcos, TX, United States. (April 12, 2024).

**68) Subbarao, M. (presenter), Jemal, M. A., Anthony, S., Mesa-Diaz, N. L., Smith, J., Vernaza, A., Du, L., Kerwin, S. M., Discover BMB, "Flow Synthesis and Cancer Cell Cytotoxicity of Caffeic Acid Phenethyl Amide (CAPA)Derivatives," ASBMB, San Antonio, TX. (March 2024).

**67) Kerwin, S. M. (Presenter), Saucedo, A. (Co-author), Mesa-Diaz, M. (Co-author), Smith, J., Vernaza, A., Du, L. (Co-author), Southwest ACS Regional Meeting, "Flow Synthesis and Cancer Cell Cytotoxicity of Caffeic Acid Phenethyl Amide (CAPA) Derivatives," American Chemical Society, Oklahoma City, OK. (November 2023).

**66) Cardus, D. (First Author/Presenter), Vernaza, A. (co-author), Smith, M. (co-author), Du, L. (Sponsor/mentor/author), 2023 The Annual Biomedical Research Conference for Minority Students (ABRCMS), "Identification of miR-506-3p Target Genes and Development of Analogs with Potentially Improved Differentiation-Inducing Activity in Neuroblastoma," Phoenix, AZ, United States. (November 15, 2023).

**65) Vernaza, A. (co-author), Du, L. (Sponsor/mentor/author), 2023 The Annual Biomedical Research Conference for Minority Students (ABRCMS), "Testing the Anti-Cancer Efficacy of miR-506-3p and Retinoic Acid in a Panel of Neuroblastoma Cell Lines," Phoenix, AZ, United States. (November 15, 2023).

**64) Cardus, D. (First Author/Presenter), Du, L. (Sponsor/mentor/author), 2023 Texas State Biomedical Sciences Summer Symposium, "that Mediate its Differentiation-Inducing Activity and Developing Differentiation- Inducing MiR-506-3p Analogs," Texas State University, San Marcos, TX, United States. (August 17, 2023).

**63) Smith, J. L. (First Author/Presenter), Aksenov, A. V. (co-author), Aksenov, N. A. (co-author), Aksenov, D. A., Scherbakov, S. V. (co-author), Kornienko, A. V. (co-author), Du, L. (Sponsor/mentor/author), Spring 2023 Undergraduate Research Conference, "Identification of Potential Anti-Cancerous Activity in Neuroblastoma from a Heterocyclic Compound Library," Texas State University, San Marcos, TX, United States. (April 20, 2023).

**62) Ghilu, S. (First Author/Presenter), Houghton, P. (Sponsor/mentor), Du, L. (Mentor), 2023 Texas State Graduate Student Research Conference, "Approaches to Identifying Drug Resistance Mechanisms in Childhood Rhabdomyosarcoma," Texas State University Graduate College, San Marcos, TX, United States. (April 4, 2023).

**61) Osorio, J. (First Author/Presenter), Betancourt, T. (Sponsor/mentor), Du, L. (Mentor), 2023 Texas PREM Conference, "Poly(lactic-co-glycolic acid)/Polyethylenimine Nanocarriers for microRNA-Mediated Reprogramming of Neuroblastoma," Texas State PERM program, San Marcos, TX, United States. (March 30, 2023).

**60) Cardus, D. (First Author/Presenter), Vernaza, A. (co-author), Smith, M. (co-author), Du, L. (Sponsor/mentor/author), 2023 Texas State STEM conference, "Identification of Potential Oncogenic Target Genes of miR-506-3p in Neuroblastoma," Texas State University, San Marcos, TX, United States. (March 24, 2023).

**59) Vernaza, A. (Presenter), Zhao, Z. (co-author), Du, L. (author/mentor/Sponsor), 2023 Texas State STEM conference, "Investigating the Oncogenic Role of CDKN3 in Neuroblastoma," Texas State University, San Marcos, TX, United States. (March 24, 2023).

**58) Ghilu, S. (First Author/Presenter), Kurmasheva, R. T., Zheng, S. (co-author), Du, L. (Mentor),

Houghton, P. J. (Sponsor/mentor), 2023 San Antonio Pediatric Cancer Symposium (SAPCS), "Approaches to Identifying Drug Resistance Mechanisms to Clinically Relevant Treatments in Childhood Rhabdomyosarcoma," GCCRI and Mays Cancer Center, San Antonio, TX, United States. (February 19, 2023).

**57) Cardus, D. (First Author/Presenter), Vernaza, A. (co-author), Smith, M. (co-author), Du, L. (Sponsor/mentor/author), 2022 The Annual Biomedical Research Conference for Minority Students (ABRCMS), "Identification of Potential Oncogenic Target Genes of miR-506-3p in Neuroblastoma," ABRCMS, Anaheim, CA, United States. (November 22, 2022).

**56) Simpson, H. N. (First Author/Presenter), Aksenov, A. V. (co-author), Aksenov, N. A. (co-author), Scherbakov, S. V. (co-author), Kornienko, A. V. (co-author), Du, L. (Sponsor/mentor/author), 2022 The Annual Biomedical Research Conference for Minority Students (ABRCMS), "Identifying Heterocyclic Compounds with Anti-Cancer Potential in Neuroblastoma," Anaheim, CA, United States. (November 22, 2022).

**55) Vernaza, A. (Presenter), Zhao, Z. (co-author), Du, L. (author/mentor/Sponsor), 2022 The Annual Biomedical Research Conference for Minority Students (ABRCMS), "Investigating the Oncogenic Role of CDKN3 in Neuroblastoma," ABRCMS, Anaheim, CA, United States. (November 22, 2022).

**54) Do, V. (First Author/Presenter), Du, L. (Sponsor/mentor), 2022 TXST ASPIRE program conference, "Identifying Heterocyclic compounds that have anti-cancer abilities in neuroblastoma cells," ASPIRE, Texas State University, San Marcos, TX. (November 18, 2022).

**53) Simpson, H. N. (First Author/Presenter), Aksenov, A. V. (co-author), Aksenov, N. A. (co-author), Scherbakov, S. V. (co-author), Kornienko, A. V., Du, L. (Sponsor/mentor/author), 2022 University of Texas at Austin Fall Undergraduate Research Symposium (UT-FURS), "Identifying Heterocyclic Compounds with Anti-Cancer Potential in Neuroblastoma," Austin, TX, United States. (September 19, 2022).

**52) $Mesa-Diaz, N. (First Author/Presenter), Du, L. (Senior author/sponsor), 2022 Spring American Chemistry Society (ACS) Conference, “Mutant miR-506-3p Oligos Promote Differentiation in Neuroblastoma Cells”. San Deigo, CA. (March 20-24, 2022).

**51) $Mesa-Diaz, N. (First Author/Presenter), Du, L. (Senior author/sponsor), 2021 The Annual Biomedical Research Conference for Minority Students (ABRCMS), "Differentiation Effects of Wildtype and Truncated miR-506-3p Mimics on Neuroblastoma Cells," ABRCMS, Virtual. (November 13, 2021).

**50) $Mesa-Diaz, N. (Oral Presenter), Du, L. (Mentor), 2021 Texas State Three Minute Thesis (3MT®) competition, "miRNA development for neuroblastoma," The Graduate College, Texas State University, San Marcos, TX. (October 27, 2021).

**49) #Maya, M. (Oral Presenter), Du, L. (Mentor), 2021 SURE Symposium, "Determining the differentiation-inducing activity of a novel miR-506-3p analog in neuroblastoma cells," Texas State SURE program, Texas State University, San Marcos, TX. (August 4, 2021).

**48) $Mesa-Diaz, N. (First Author/Presenter), Zhao, Z. (co-author), Du, L. (Senior author/sponsor), 2021 International Research Conference (IRC) for Graduate Students, "Investigating the Differentiation Inducing Activity of Wildtype & Mutant 506-3p Mimics," Texas State University, Virtual meeting, San Marcos, TX, United States. (April 6, 2021).

**47) $Baker, A. L. (First Author/Presenter), Zhao, Z. (co-author), Du, L. (Senior author/sponsor), 2021 International Research Conference (IRC) for Graduate Students, "Investigating the role of SAPCD2 in modulating neuroblastoma cell survival and differentiation," Texas State University, Virtual meeting, San Marcos, TX, United States. (April 6, 2021).

**46) #Maya, M. (Oral Presenter), Du, L. (Mentor), 2021 SURE oral presentation, "Determining the differentiation-inducing activity of a novel miR-506-3p analog in neuroblastoma cells," Texas State

SURE program, Texas State University, San Marcos, TX. (July 15, 2021).

**45) #Vernaza, A. (First Author/Presenter), Du, L. (sponsor), 2021 STEM Undergraduate Research Experience (SURE), "Investigating the Oncogenic Role of CDKN3 in Neuroblastoma," Texas State University, San Marcos, TX, United States. (March 3, 2021).

**44) #Maya, M. (Oral Presenter), Du, L. (Mentor), 2021 SURE oral presentation, "Determining the differentiation-inducing activity of a novel miR-506-3p analog in neuroblastoma cells," Texas State SURE program, Texas State University, San Marcos, TX. (July 15, 2021).

43) #Vernaza, A. (First Author/Presenter), Zhao, Z. (co-author), Du, L. (Senior author/sponsor), 2020 STEM Undergraduate Research Experience (SURE), "Investigating the Oncogenic Role of CDKN3 in Neuroblastoma," Texas State University, San Marcos, TX, United States. (August 2020). Virtual.

42) $Oviedo, A. (First Author/Presenter), Zhao, Z. (co-author), Kornienko, A. V. (author), Du, L. (Senior author/sponsor), 2020 Women in Science and Engineering Conference (WISE), "Characterizing the differentiation-inducing activity of ChemBridge small molecules in neuroblastoma cell lines with different genetic background," Texas State University, San Marcos, TX, United States. (March 6, 2020).

41) $Baker, A. L. (First Author/Presenter), Zhao, Z. (co-author), Du, L. (Senior author/sponsor), 2020 Women in Science and Engineering Conference (WISE), "Identification of a Novel Oncogene SAPCD2 in Pediatric Neuroblastoma," Texas State University, San Marcos, TX, United States. (March 6, 2020).

40) $Belnap, N. (First Author/Presenter), Zhao, Z. (co-author), Du, L. (Senior author/sponsor), 2020 Women in Science and Engineering Conference (WISE), "Investigating the Cellular Responses of Neuroblastoma Cells to the Over-Expression of miR-506-3p," Texas State University, San Marcos, TX, United States. (March 6, 2020).

39) $Oviedo, A., Zhao, Z., Du, L. The Annual Biomedical Research Conference for Minority Students (ABRCMS) 2019, "Characterizing the Activity of Three Novel Differentiation-inducing Small Compounds in Neuroblastoma Cell Lines," ABRCMS, Anaheim, CA, United States. (November 13, 2019).

38) $Baker, A. L., Zhao, Z., **Du, L.** The 11th Annual International Research Conference (IRC) 2019, "Cell Cycle Regulator SAPCD2 Contributes to Poor Prognosis in Pediatric Neuroblastoma," Texas State University, San Marcos, TX, United States. (November 5, 2019).

37) $Oviedo, A., Zhao, Z., **Du, L.** The 11th Annual International Research Conference (IRC) 2019, "Discovery of novel differentiation-inducing compounds for treating neuroblastoma cell lines," Texas State University, San Marcos, TX, United States. (November 5, 2019).

36) #Gonzales, A., Zhao, Z., **Du, L.**, The 2nd Annual Undergraduate Research Symposium 2019, "Characterizing The Activity of a Novel Differentiation-Inducing Compound in Neuroblastoma Cells," Texas State University, San Marcos, CA, United States. (August 2, 2019).

35) $Laguera, B., Zhao, Z., **Du, L.**, Kornienko, A. 2019 Center of Innovative Drug Design (CIDD) Drug Discovery Symposium, "Novel Neuroblastoma Differentiating Agents," University of Texas at San Antonio, San Antonio, TX, United States. (April 29, 2019).

34) #Johns, A., Zhao, Z., **Du, L.**, Kornienko, A. 2019 Center of Innovative Drug Design (CIDD) Drug Discovery Symposium, "Structure Activity Relationship Study of a Novel Neuroblastoma Differentiation Agent," University of Texas at San Antonio, San Antonio, TX, United States. (April 29, 2019).

33) $Oviedo, A., Zhao, Z., Kornienko, A. V., **Du, L.** 2019 Women in Science and Engineering Conference (WISE), "Characterizing activity of three novel differentiation-inducing small synthetic compounds in neuroblastoma cell line BE(2)-C," Texas State University, San Marcos, TX, United

States. (March 8, 2019).

32) #Johns, A., Zhao, Z., **Du, L.**, Kornienko, A. 2018 UTSA College of Sciences Research in Service for a Better Tomorrow conference, "Preparation of a Mechanistic Probe for a Neuroblastoma Differentiation Agent," University of Texas at San Antonio, San Antonio, TX, United States. (October 5, 2018).

31) #Johns, A., Zhao, Z., **Du, L.**, Kornienko, A. 2018 The 12th Annual Undergraduate Research Conference of Texas State, "Preparation of a Mechanistic Probe for a Neuroblastoma Differentiation Agent," Texas State University, San Marcos, TX, United States. (April 20, 2018).

30) #Johns, A., Hooper, A., Zhao, Z., **Du, L.**, Kornienko, A. Texas State Chemistry & Biochemistry Colloquium, "Preparation of a Mechanistic Probe for a Neuroblastoma Differentiation Agent," Texas State University, Dept of Chemistry and Biochemistry, San Marcos, TX, United States. (April 6, 2018).

29) #Shelton, S. D., Zhao, Z., **Du, L.**, Texas State Chemistry & Biochemistry Colloquium, "RXRA is a direct target gene of miR-506-3p that regulates MYCN expression and cell differentiation in neuroblastoma," Texas State University, Dept of Chemistry and Biochemistry, San Marcos, TX, United States. (April 6, 2018). Oral presentation.

28) #Shelton, S. D., Zhao, Z., **Du, L.**, Central Texas Region American Chemical Society Centennial Celebration, "RXRA is a direct target gene of miR-506-3p that regulates MYCN expression and cell differentiation in neuroblastoma," Central Texas American Chemistry Society, Oasis Restaurant on Lake Travis, Austin, TX, United States. (November 10, 2017).

27) $Medrano, G., Zhao, Z., **Du, L.**, Ninth Annual International Research Conference for Graduate Students, "The Role of the Vacuolar (H+)-ATPase in Neuroblastoma Cell Differentiation induced by microRNA-506-3p," Texas State University, San Marcos, TX, United States. (November 7, 2017).

26) #Shelton, S. D., Zhao, Z., **Du, L.**, UT Health San Antonio, Department of Biochemistry and Structural Biology Annual Retreat, "RXRA is a direct target gene of miR-506-3p that regulates MYCN expression and cell differentiation in neuroblastoma," UT Health Science Center at San Antonio, GCCRI building, San Antonio, TX, United States. (November 3, 2017).

25) $Medrano, G., Zhao, Z., **Du, L.**, Summer Capstone Symposium, "Determining the Function of Vacuolar (H+)-ATPase in Regulating Neuroblastoma Cell Survival and Differentiation," UT Health Science Center at San Anotonio, San Antonio, TX, United States. (August 11, 2017).

24) #Shelton, S. D., Zhao, Z., **Du, L.**, SMBE 2017: Annual Meeting of the Society of Molecular Biology and Evolution, "Defining the mechanisms by which miR-506-3p regulates MYCN expression," SMBE, JW Marriott Austin Hotel, Austin, TX, United States. (July 1, 2017).

23) Betancourt, T., **Du, L.**, Kornienko, A. V., Kerwin, S. M., Irvin, J. A., Lewis, L., Beall, G. W., Texas State University Health Scholar Showcase, "Drug Delivery and Therapeutics Research," Texas State University, San Marcos, TX. (February 2017).

22) Betancourt, T., David, W., **Du, L.**, Kang, H.-G., Kerwin, S., Lewis, K., Sun, S., Zhao, Q., 2017 Health Scholar Showcase, "Cancer, Genetics, and Bioinformatics," Texas State University, San Marcos, TX, United States. (February 10, 2017).

21) Ma, X., Li, M., Zhao, Z., Pertsemlidis, A., Sung, D., **Du, L.**, Greehey Children's Cancer Research Institute 2014 Symposium, "Crosstalk between MYCN and differentiation-inducing microRNAs in neuroblastoma," The University of Texas Health Science Center, Greehey Children's Cancer Research Institute, San Antonio, TX, United States. (November 21, 2014).

20) Zhao, Z., Ma, X., Li, M., Kosti, A., Lin, G., Chen, Y., Pertsemlidis, A., HIsao, T. H., **Du, L.**, Greehey Children's Cancer Research Institute 2014 Symposium, "microRNA-449a functions as a

tumor suppressor in neuroblastoma through inducing cell differentiation and cell cycle arrest," The University of Texas Health Science Center, Greehey Children's Cancer Research Institute, San Antonio, TX, United States. (November 21, 2014).

19) Li, M., Ma, X. (co-author), Pertsemlidis, A., **Du, L.**, The University of Texas Health Science Center 2014 Summer research Program, "MYCN regulates the response of neuroblastoma cells to differentiation-inducing microRNAs," The University of Texas Health Science Center, Greehey Children's Cancer Research Institute, San Antonio, TX, United States. (August 5, 2014).

18) DeSevo, C., **Du, L.**, Behrens, C. F., Wistuba, I. I., Minna, J. D., Pertsemlidis, A., Cancer Prevention and Research Institute of Texas, "miR-10a regulation of PIK3CA, Innovations in Cancer Prevention and Research Conference," Austin, TX, United States. (November 15, 2011).

17) **Du, L.**, Subauste, M. C., Baker, M. F., DeSevo, C., Borkowski, R., Zhong, S., Schageman,

J. J., Greer, R. M., Yang, C., Gazdar, A. F., Wistuba, I., Minna, J. D., Pertsemlidis, A., Cancer Prevention and Research Institute of Texas, "miR-337-3p modulates sensitivity to paclitaxel in non-small cell lung cancer by down-regulating STAT3 and RAP1A," Austin, TX, United States. (November 17, 2010).

16) Borkowski, R., **Du, L.**, Gazdar, A. F., Minna, J. D., Pertsemlidis, A., 60th Annual Meeting of the American Society of Human Genetics, "An miRNA inhibitor screen for KRAS- selectively lethal miRNAs," Washington, DC, United States. (November 2, 2010).

15) Gibbons, D. L., Gregory, P. A., Lin, W., **Du, L.**, Creighton, C., Pertsemlidis, A., Kurie, J., Keystone Symposium on miRNA and Cancer, "A murine model of NSCLC demonstrates a role for the miR-200 family in regulating EMT and metastasis," Denver, CO, United States. (June 10, 2009).

14) **Du, L.**, Greer, R. M., Saber, B., Gazdar, A., White, M. A., Minna, J. D., Pertsemlidis, A., Keystone Symposium on miRNA and Cancer, "miR-337 modulates sensitivity to paclitaxel in non-small cell lung cancer," Denver, CO, United States. (June 10, 2009).

13) **Du, L.**, Greer, R., Saber, B., Gazdar, A. F., White, M. I., Minna, J. D., Pertsemlidis, A., 100th Annual Meeting of the American Association of Cancer Research, "miR-337-3p modulates sensitivity to paclitaxel in non-small cell lung cancer," Denver, CO, United States. (April 2009).

12) Pertsemlidis, A., **Du, L.**, Greer, R., Gazdar, A. F., Hammond, S., White, M., Minna, J. D., 58th Annual Meeting of the American Society of Human Genetics, "microRNA regulation of chemoresistance in NSCLC," Philadelphia, PA, United States. (November 11, 2008).

11) **Du, L.**, Schageman, J., Hammond, S., Prudkin, L., Wistuba, I. I., Ji, L., Roth, J. A., Minna, J., pertsemlidis, A., 58th Annual Meeting of the American Society of Human Genetics, "miR- 93, miR-98 and miR-197 regulate expression of tumor suppressor gene FUS1," Philadelphia, PA, United States. (November 11, 2008).

10) **Du, L.**, Greer, R. M., Schageman, J., Gazdar, A. F., Hammond, S., White, M., Minna, J., pertsemlidis, A., Proceedings of the 99th Annual Meeting of the American Association for Cancer Research, "microRNA regulation of chemoresistance in non-small cell lung cancer (NSCLC)," San Diego, CA, United States. (April 12, 2008).

9) Pertsemlidis, A., **Du, L.**, Greer, R. M., Schageman, J., Girard, L., Peyton, M., Gazdar, A. F., Hammond, S., Minna, J., Keystone Symposium on MicroRNA and Cancer, "microRNAs modulate chemotherapy sensitivity of non-small cell lung cancer (NSCLC)," Keystone, CO, United States. (June 18, 2007).

8) **Du, L.**, Schageman, J., Goodson, S., Thompson, J. M., Greer, R., Hammond, S., Girard, L., Sato, M., Peyton, M., Gazdar, A. F., Minna, J., Pertsemlidis, A., Fourth Annual Postdoctoral Symposium & Poster Session, "Elucidating the role of microRNAs in lung cancer," The University of Texas Southwestern Medical Center at Dallas, New Orleans, LA, United States. (2006).

7) Pertsemlidis, A., Inorv., **Du, L.**, Schageman, J., Goodson, S., Thompson, J. M., Hammond, S., Girard, L., Sato, M., Shay, J., Gazdar, A. F., Minna, J., 56th Annual Meeting of the American Society of Human Genetics, "MicroRNA expression profiling of lung cancer cell lines," American Society of

Human Genetics, New Orleans, LA, United States. (October 9, 2006).

6) **Du, L.**, Schageman, J., Minna, J., pertsemlidis, A., Third Annual Postdoctoral Symposium & Poster Session, "miR-98 as a Potential Diagnostic Marker and Therapeutic Target in Lung Cancer," The University of Texas Southwestern Medical Center at Dallas, Dallas, TX, United States. (2005).

5) **Du, L.**, Post, S., Cardiovascular Research Day., "M-CSF Regulates Expression of the Adaptor Protein Dab2," Linda & Jack Gill Heart Institute, University of Kentucky, Lexington, KY, United States. (2003).

4) **Du, L.**, Post, S., Southeast Lipid Research Conference, "Differential Regulation of LDL and Transferrin Receptor Endocytosis: Potential involvement of receptor-specific adaptor proteins," American Heart Association, Pine Mountain, GA, United States. (March 2002).

3) **Du, L.**, Post, S., Cardiovascular Research Day., "Differential Regulation of Transferrin and LDL Receptors by Macrophage-Colony Stimulating Factor," Linda & Jack Gill Heart Institute, University of Kentucky, Lexington, KY, United States. (2001).

2) **Du, L.**, Post, S., 2nd Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology, "Macrophage-Colony Stimulating Factor Differentially Regulates Transferrin and LDL Receptors in Macrophages," American Heart Association, Arlington, VA, United States. (2001).

1) **Du, L.**, Post, S., Cardiovascular Research Day., "Macrophage-Colony Stimulating Factor Regulates Transferrin Association with Macrophages via a PI3-Kinase Signaling Pathway," Linda & Jack Gill Heart Institute, University of Kentucky, Lexington, KY, United States. (2000).

4. Published Abstracts: (total, 20; ****, since 2021, 1**)**
(#, undergraduate in my lab; $, graduate in my lab)

20) [$]Mesa-Diaz, N., & **Du, L. (2021). Developing miR-506-3p Mimics with Enhanced Differentiation-Inducing Activity. *FASEB Journal*, *35*(No.1 Suppl). https://www.fasebj.org/doi/abs/10.1096/fasebj.2019.33.1_supplement.634.5

19) [$]Baker, L. A., Zhao, Z., **Du, L.** (April 19, 2020). Investigation of the Oncogenic Role of the Cell Cycle Regulator SAPCD2 in Pediatric Neuroblastoma. *FASEB Journal*, *34* (No.1 Suppl). https://faseb.onlinelibrary.wiley.com/doi/abs/10.1096/fasebj.2020.34.s1.09263

18) [$]Jemal, M. A., Schwartz, Z. T., Zhao, Z., **Du, L.**, Kerwin K. M. (April 2019). Overcoming the Rapid Metabolism of the Promising Anticancer Natural Product Rooperol. *FASEB Journal*, *33*(No.1 Suppl).

https://www.fasebj.org/doi/abs/10.1096/fasebj.2019.33.1_supplement.634.5

17) [#]Shelton, S. D., Zhao, Z., **Du, L.** RXRA is a direct target gene of miR-506-3p that regulates oncogene MYCN expression and cell differentiation in neuroblastoma. *FASEB Journal*, *32*(No.1 Suppl). (April, 2018). https://www.fasebj.org/content/32/1_Supplement/804.16

16) [$]Medrano, G., Zhao, Z., **Du, L**. The Role of the Vacuolar (H+)-ATPase in Neuroblastoma Cell Differentiation induced by microRNA 506-3p. *FASEB Journal*, *32*(No.1 Suppl). (April, 2018). www.fasebj.org/content/32/1_Supplement/804.3

15) [$]Sousares, M., **Du, L.**, MicroRNA-506-3p as a Differentiation Agent for Neuroblastoma. (April, 2017). *FASEB Journal*, *31*(No.1 Suppl). www.fasebj.org/content/31/1_Supplement/757.18

14) [$]Partridge, V., **Du, L.**, The Role of CDKN3 in Neuroblastoma Differentiation. *FASEB Journal*, *31*(No.1 Suppl). (April, 2017). http://www.fasebj.org/action/doSearch?AllField=The+Role+of+CDKN3+in+Neuroblastoma+Differentiation

13) Zhang, Y., Ma, X., Yu, X., Patolia, H., Zhao, Z., **Du, L.**, & Pertsemilidis, A. (2017).

ncRNA regulation of eribulin response in neuroblastoma. *Cancer Research*, *77*(13 Supplement). https://cancerres.aacrjournals.org/content/77/13_Supplement/3506

12) Yu, X., Ma, X., Zhang, Y., Zhao, Z., **Du, L.**, & Pertsemilidis, A. (2017). Therapeutic potential of miR-195 in nonsmall cell lung cancer. *Cancer Research*, *77*(13 Supplement). https://cancerres.aacrjournals.org/content/77/13_Supplement/5444

11) Yu, X., Zhao, Z., Ma, X., **Du, L.**, & Pertsemilidis, A. (2016). miR-195 represses the tumorigenesis of non-small cell lung cancer and synergizes with microtubule targeting agents. *Cancer Research*, *76*(14 Supplement). https://cancerres.aacrjournals.org/content/76/14_Supplement/1063

10) Ma, X., Yu, X., Zhao, Z., Patolia, H., **Du, L.**, & Pertsemilidis, A. (2016). Non-coding RNA regulation of eribulin response in neuroblastoma. *Cancer Research*, *76*(14 Supplement). https://cancerres.aacrjournals.org/content/76/14_Supplement/1940

9) Yu, X., Zhao, Z., Ma, X., **Du, L.**, Pertsemlidis, A., Proceedings of the 105th Annual Meeting of the American Association for Cancer Research, "A high-throughput screen identifies microRNAs regulating lung cancer cell survival and response to paclitaxel," San Diego, CA, United States. (April 5, 2014). *Cancer Research*, *74*(19 Supplement). https://cancerres.aacrjournals.org/content/74/19_Supplement/3545

8) Zhao, Z., Ma, X., Hsiao, T.-H., Chen, Y., Suraokar, M., Wistuba, I., Minna, J. D., Pertsemlidis, A., **Du, L.**, Proceedings of the 105th Annual Meeting of the American Association for Cancer Research, "LMO1 is a novel oncogene in neuroendocrine lung cancer," San Diego, CA, United States. (April 5, 2014). *Cancer Research*, *74*(19 Supplement). https://cancerres.aacrjournals.org/content/74/19_Supplement/466

7) DeSevo, C., **Du, L.**, Behrens, C., Wistuba, I., Minna, J. D., & Pertsemilidis, A. (2013). miR- 10a regulates PI3K signaling and paclitaxel response in NSCLC. *Cancer Research*, *73*(8 Supplement). https://cancerres.aacrjournals.org/content/73/8_Supplement/3049

6) **Du, L.**, Zhao, Z., Hsiao, T.-H., Chen, Y. F., Young, E., Suraokar, M., Wistuba, I., Minna, J. D., Pertsemlidis, A., Proceedings of the 104th Annual Meeting of the American Association for Cancer Research, "miR-93-directed down-regulation of DAB2 defines a novel oncogenic pathway in lung cancer," Washington DC, United States. (April 6, 2013). *Cancer Research*, *73*(8 Supplement). https://cancerres.aacrjournals.org/content/73/8_Supplement/3096

5) **Du, L.**, DeSevo, C., Borkowski, R., Baker, M., Minna, J. D., & Pertsemilidis, A. (2012). microRNA regulation of cell viability and drug response in cancer. *Cancer Res*, *72*(8 Supplement). https://cancerres.aacrjournals.org/content/72/8_Supplement/140

4) DeSevo, C., **Du, L.**, Behrens, C., Minna, J. D., & Pertsemilidis, A. (2012). miR-10a regulation of PIK3CA and response to taxol in non-small cell lung cancer. *Cancer Res*, *72*(2 Supplement). https://cancerres.aacrjournals.org/content/72/2_Supplement/A2

3) **Du, L.**, DeSevo, C., Borkowski, R. F., Baker, M., Gazdar, A. F., Minna, J. D., Pertsemlidis, A., Noncoding RNAs and Cancer, American Association for Cancer Research, "microRNA regulation of cell viability and drug sensitivity in lung cancer," Miami Beach, FL, United States. (January 8, 2012). *Cancer Res*, *72*(2 Supplement). https://cancerres.aacrjournals.org/content/72/2_Supplement/B7

2) Borkowski, R., **Du, L.**, Minna, J. D., Gazdar, A., Pertsemlidis, A., Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research, "A miRNA inhibitor screen for synthetic lethal interactions in KRAS-driven NSCLC," Orlando, FL, United States. (April 2, 2011). *Cancer Res*, *71*(8 Supplement). https://cancerres.aacrjournals.org/content/71/8_Supplement/3958

1) **Du, L.**, Subauste, M. C., Baker, M. D., DeSevo, C., Borkowski, R., Zhong, S., Schageman, J. J., Greer, R. M., Yang, C. R., Girard, L., Gazdar, A. F., Wistuba, I. I., Minna, J. D., Pertsemlidis, A.,

Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research, "miR-337-3p and its targets STAT3 and RAP1A modulate paclitaxel sensitivity in non-small cell lung cancers (NSCLCs)," Orlando, FL, United States. (April 2. 2011). *Cancer Res*, *71*(8 Supplement) https://cancerres.aacrjournals.org/content/71/8_Supplement/4709

5. Invited Talks, Lectures, and Presentations: (total, 21; ****, since 2021, 4)**

21) **Du, L. (Presenter), 2025 9th Global Virtual Conference on Pediatrics and Neonatology, "The cell differentiation pathways and differentiation therapy in neuroblastoma," Virtual, United States. (August 11, 2025).

20) **Du, L. (Presenter), 2022 Global Virtual Conference on Pediatrics and Neonatology, "Cell differentiation and differentiation therapy in neuroblastoma," Virtual. (November 21, 2022).

19) **Du, L. (Presenter), 2022 2nd Global Virtual Summit on Pediatrics & Neonatology, "Targeting the cell differentiation pathway in neuroblastoma treatment," Virtual. (September 19, 2022).

18) **Du L., Targeting the cell differentiation pathway in neuroblastoma treatment. Department of Biology Seminar, Middle Tennessee State University. Virtual (April 14, 2022).

17) **Du, L.**, Beijing University of Chinese Medicine Pain Management Forum 2019, "From raising a scientific question to a successful grant application," Dong Fang Hospital, Beijing University of Chinese Medicine, Beijing, China. (July 7, 2019).

16) **Du, L.**, 3rd World Congress on Cancer Biology and Immunology 2019, "Mechanisms of cell differentiation in neuroblastoma and discovery of differentiation agents for neuroblastoma therapy," Cenetri Publishing group, Klima Hotel Milano Fiere, Milan, Italy, Milan, Italy. (March 11, 2019).

15) **Du, L.**, International Conference and Exhibition on Pediatric Oncology and Clincial Pediatrics, "Cell differentiation and differentiation therapy in neuroblastoma," Conference Series LLC, Pediatric Oncology, Pediatric Leukemia, Pediatric Hematology Oncology & Neuroblastoma in Children, Toronto, Canada. (August 11, 2016).

14) **Du, L.**, Department of Chemistry and Biochemistry. Texas State University, "Cell differentiation and differentiation therapy in neuroblastoma," San Marcos, TX. (November 23, 2015).

13) **Du, L.**, Innovative Drug Discovery & Nanotechnology session, "Identifying novel differentiation agents for neuroblastoma therapy," 2015 Drug Discovery and Therapy World Congress, Boston, United States. (July 23, 2015).

12) **Du, L.**, Session 603: Lead Discovery and Optimization, "Using high-content screening to identify novel differentiation agents for neuroblastoma," 2015 BIT‘s 8th Annual World Cancer Congress, Beijing, China. (May 16, 2015).

11) **Du, L.**, Department of Chemistry and Biochemistry. Texas State University, "Targeting the differentiation pathway in neuroblastoma differentiation therapy," San Marcos, TX. (December 4, 2014).

10) **Du, L.**, 2014 EDT Program Retreat, "Differentiation therapy in neuroblastoma," Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX. (November 7, 2014).

9) **Du, L.**, 2014 Cancer Therapy and Research Center Symposium, "Targeting the differentiation pathway in neuroblastoma differentiation therapy," University of Texas Health Science Center at San Antonio, San Antonio, TX. (September 26, 2014).

8) **Du, L.**, Pediatric Translational Working Group, "Targeting the differentiation pathway in

neuroblastoma differentiation therapy," Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX. (July 29, 2014).

7) **Du, L.**, Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, "Cell differentiation in neuroblastoma," Baton Rouge, LA. (April 16, 2014).

6) **Du, L.**, "Drug/target discovery for neuroblastoma differentiation therapy," Department of Pediatrics Research Day. University of Texas Health Science Center at San Antonio, San Antonio, TX. (May 10, 2013).

5) **Du, L.**, Greehey Children's Cancer research Institute Annual Retreat, "Cell differentiation in neuroblastoma," University of Texas Health Science Center at San Antonio, San Antonio, TX. (February 28, 2013).

4) **Du, L.**, Department of Cellular and Structural Biology Seminar series, "The roles of microRNAs and transcription factors in lung cancer," University of Texas Health Science Center at San Antonio, San Antonio, TX. (October 16, 2012).

3) **Du, L.**, Department of Cellular and Structural Biology Annual Retreat, "From lung to pediatric cancers: how do I bridge the two?," University of Texas Health Science Center at San Antonio, San Antonio, TX. (May 17, 2012).

2) **Du, L**., "Inter-regulation between miRNAs and STAT3 in lung cancer," Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX. (April 8, 2011).

1) **Du, L.**, Mini-symposium. The 102nd Annual Meeting of the American Association for Cancer Research, "miR-337-3p and its targets STAT3 and RAP1A modulate paclitaxel sensitivity in non-small cell lung cancer (NSCLC)," Orlando, FL. (April 4, 2011).

III. SERVICE

A. Institutional (Texas State)

1. University: (**, since 2021, 3)

**7) Representative, Bobcat Day. (October 25, 2025).

**6) Faculty respondent, 2021 International Research Conference (Faculty Respondent). (April 6, 2021 - April 8, 2021).

**5) Reviewer, STEM Undergraduate Research Experience (SURE) program (Application Reviewer). (March 2021).

4) Poster Judge, 2020 Women in Science and Engineering Conference (WISE). (March 6, 2020).

3) Poster Judge, The 2nd Annual Undergraduate Research Symposium 2019. (August 2, 2019).

2) Ad Hoc reviewer, 2019 SURE program applications. (March 2019).

1) Poster Judge, Ninth Annual International Research Conference for Graduate Students. (November 8, 2017).

2. College: (**, since 2021)

**Representative, CoSE undergraduate Scholarship Committee. (2025 - Present).

**Representative, COSE Undergraduate Scholarship Committee. (2021 – 2023).

2. Department: (<u>, since 2021, 10</u>)**

**13) Member, Department safety committee. (2025 - Present).

**12) Member, IMBC admission committee. (2025 - Present).

**11) Chair, Faculty Evaluation Committee. (2022 – 2023 cycle).

**10) Chair, Biochem Teaching lab Ad Hoc committee. (September 2021 – December 2022)).

**9) Member, Department Personnel Committee. (2021 - Present).

**8) Member, Department Space Committee. (2021 - Present).

**7) Member, Faculty Evaluation Committee. (2021-2022 cycle).

**6) Member, Physical Chemistry Faculty Search Committee. (June 2021 - March 2022).

**5) Biochemistry Graduate Curriculum committee. (2016 - Present).

**4) Biochemistry Curriculum committee. (2015 - Present).

3) Member, Inorganic Chemistry Faculty Search Committee. (June 2018 - March 2019).

2) Judge for oral presentation, Texas State Chemistry & Biochemistry Colloquium. (April 6, 2018).

1) Member, Department Biochemistry Faculty Search Committee. (June 2017 - March 2018).

B. Professional

1. Conference Organizing Committee: (<u>, since 2021,2</u>)**

**4) Section moderator, 2025 9th Global Virtual Conference on Pediatrics and Neonatology, The cell differentiation pathways and differentiation therapy in neuroblastoma," Virtual. (August 11, 2025).

**3) Section moderator, 2022 Global Virtual Conference on Pediatrics and Neonatology. Virtual. (November 21, 2022 - November 22, 2022).

2) Organizer/Moderator, 3rd World Congress on Cancer Biology and Immunology, Milan, Italy. (July 25, 2018 – March 2019).

1) Co-Chair, International Conference and Exhibition on Pediatric Oncology and Clinical Pediatrics, Toronto, Canada. (August 11, 2016).

2. Journal Editorial Board: (<u>, since 2021</u>)**

**3) Editorial Review Board Member, Technology in Cancer Research and Treatment (TCRT). (October 2021 - Present).

**2) Advances in Modern Oncology Research. (2015 - Present).

**1) Editorial Board: RNA and Disease. (2014 - Present).

3. Grant Reviewer:

4) Department of Defense CDMRP Neuroblastoma - Pediatric Brain Tumors (NB-PBT) Panel, Washington, DC. (October 6, 2017 – December 1, 2017).

3) Department of Defense CDMRP LCRO Concept Award, online. (September 2016).

2) Institute for Integration of Medicine and Science at San Antonio (2014).

1) St. Baldrick's Foundation Childhood Cancer Research Grants (2015, institution internal reviewer)

4. Journal Article Reviewer: (<u>, since 2021</u>)**

**28) Reviewer / Referee, British Journal of Cancer (IF 6.8). (October 2025).

**27) Reviewer / Referee, Molecular Carcinogenesis (IF 3.2). (June 2025).

**26) Reviewer / Referee, Clinical and Translational Discovery (IF 1.9). (November 2023).

**25) Reviewer / Referee, Cell Biochemistry & Function (IF 2.8). (October 2023).

**24) Oncogenesis (IF 7.485). (Apr, May 2022).

**23) Technology in Cancer Research & Treatment (IF 2.068). (Feb, 2021, Jul. 2021, Jan. 2022).

**22) Journal of Experimental and Clinical Cancer Research (IF 5.646). (Sep. 2019, Mar. 2020, July 2020, May 2021, Jul. 2021, Jan. 2022, Apr. 2022).

21) Cancer Management and Research (IF 3.702). (Mar. 2020).

20) Endocrine Connections (IF 2.474). (Mar. 2020).

19) BMC Cancer (IF 3.288). (Feb. 2020).

18) Biological Chemistry (IF 4.106). (Apr. 2019).

17) Cancer Biology & Therapy (IF 2.879). (Apr. 2019).

16) Molecular Oncology (IF 5.264). (Apr. 2019).

15) Cell Proliferation (IF 5.039). (Aug. 2018).

14) Oncotarget (IF 3.710). (Jun. 2017).

13) BMC Genomics (3.730). (Mar. 2016).

12) Advances in Modern Oncology Research. (Dec. 2015, Aug. 2016).

11) Molecular Carcinogenesis (IF 3.411). (Oct. 2013, Jul. 2015, Mar. 2018).

10) Molecular Cancer (IF 10.679). (Jul. 2014, May 2015).

9) International Journal of Biochemistry and Cell Biology (IF 4.240). (Nov. 2013).

8) British Journal of Cancer (IF 5.416). (Oct. 2012).

7) Frontiers in non-coding RNA. (Sep. 2012).

6) Biologics: targets and Therapy (IF 2.00). (May 2011).

5) International Journal of Nanomedicine (IF 4.471). (Aug. 2011).

4) Journal of Experimental Pharmacology (IF 3.867). (Feb. 2011).

3) Translational Research (IF 4.915). (Dec. 2010).

2) Laboratory Investigation (IF 3.684). (Sep. 2010).

1) Lung Cancer: Targets and Therapy (IF 3.12). (Apr. 2010, Jun. 2020).

C. Organization Memberships

Children's Oncology Group. (2013 - Present).

American Association of Cancer Research. (2008 - Present).